

1 **An IFN-STAT1-CYBB Axis Defines Protective Plasmacytoid DC to**  
2 **Neutrophil Crosstalk During *Aspergillus fumigatus* Infection.**

3

4 Yahui Guo<sup>1,2,3</sup>, Mariano A. Aufiero<sup>1,2,3,4</sup>, Kathleen A.M. Mills<sup>1,2,3,5</sup>, Simon A. Grassmann<sup>3</sup>,  
5 Hyunu Kim<sup>3</sup>, Paul Zumbo<sup>6</sup>, Mergim Gjonbalaj<sup>1,2,3</sup>, Audrey Billips<sup>1,2,3</sup>, Katrina B. Mar<sup>1,2,3</sup>, Yao  
6 Yu<sup>1,2,3</sup>, Doron Betel<sup>7</sup>, Joseph C. Sun<sup>3</sup>, Tobias M. Hohl<sup>1,2,3,4,5,#</sup>

7

8 <sup>1</sup>Infectious Disease Service, Department of Medicine, and <sup>2</sup>Human Oncology and Pathogenesis  
9 Program, and <sup>3</sup>Immunology Program, <sup>4</sup>Louis V. Gerstner Jr. Graduate School of Biomedical  
10 Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York,  
11 NY10065, USA

12 <sup>5</sup>Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School,  
13 New York, NY 10065, USA

14 <sup>6</sup>Applied Bioinformatics Core, Department of Physiology and Biophysics, Weill Cornell  
15 Medicine, New York, NY 10065, USA.

16 <sup>7</sup>Applied Bioinformatics Core, Division of Hematology and Medical Oncology, Department of  
17 Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY  
18 10065, USA.

19

20

21 #, Corresponding author and lead contact. E-mail: [hohlt@mskcc.org](mailto:hohlt@mskcc.org) (T.M.H.)

22

23

24 **Footnote**

25 #Address correspondence to:

26 Tobias M. Hohl, MD, PhD

27 Memorial Sloan Kettering Cancer Center

28 1275 York Avenue, Box 9

29 New York, NY 10065

30 Phone: 646-888-3596

31 Fax: 646-422-0502

32 [hohlt@mskcc.org](mailto:hohlt@mskcc.org)

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Abstract**

48 *Aspergillus fumigatus* is the most common cause of invasive aspergillosis (IA), a devastating  
49 infection in immunocompromised patients. Plasmacytoid dendritic cells (pDCs) regulate host  
50 defense against IA by enhancing neutrophil antifungal properties in the lung. Here, we define the  
51 pDC activation trajectory during *A. fumigatus* infection and the molecular events that underlie  
52 the protective pDC - neutrophil crosstalk. Fungus-induced pDC activation begins after bone  
53 marrow egress and results in pDC-dependent regulation of lung type I and type III IFN levels.  
54 These pDC-derived products act on type I and type III IFN receptor-expressing neutrophils and  
55 control neutrophil fungicidal activity and reactive oxygen species production via STAT1  
56 signaling in a cell-intrinsic manner. Mechanistically, neutrophil STAT1 signaling regulates the  
57 transcription and expression of *Cybb*, which encodes one of five NADPH oxidase subunits. Thus,  
58 pDCs regulate neutrophil-dependent immunity against inhaled molds by controlling the local  
59 expression of a subunit required for NADPH oxidase assembly and activity in the lung.

60

61 **Keywords:** *Aspergillus fumigatus*, plasmacytoid DC, neutrophil, interferons, STAT1, NADPH  
62 oxidase, *Cybb*, lung, fungus, crosstalk

63

## 64 **Introduction**

65 Invasive pulmonary aspergillosis, a life-threatening mold infection, occurs when the  
66 respiratory immune system fails to eradicate ubiquitous inhaled *Aspergillus* spores (i.e., conidia)  
67 prior to their germination into tissue-invasive hyphae (Thompson and Young, 2021). At-risk  
68 populations include patients with acute leukemia and other bone marrow disorders, recipients of  
69 hematopoietic cell and lung transplants, individuals with immune-related or neoplastic diseases  
70 treated with prolonged corticosteroid therapy or with novel targeted biologics (e.g., ibrutinib)  
71 that blunt fungal immune surveillance pathways (Desai et al., 2024; Lionakis et al., 2017;  
72 Varughese et al., 2018) and patients with severe respiratory virus infections, including influenza  
73 and COVID-19 (Feys et al., 2024; Hoenigl et al., 2022). As a result of these medical advances  
74 and global pandemic viruses, *A. fumigatus* has become the most common agent of mold  
75 pneumonia worldwide (Brown et al., 2012; Feys et al., 2024; Latgé and Chamilos, 2019;  
76 Lionakis et al., 2023; Lionakis and Levitz, 2018; Mills et al., 2024; Tischler and Hohl, 2019).

77 Host defense against airborne mold conidia depends on intact myeloid cell numbers and  
78 function at the respiratory mucosa. Lung-infiltrating neutrophils and monocyte-derived dendritic  
79 cells (Mo-DCs) play essential roles in killing phagocytosed conidia, with a central role for  
80 products of NADPH oxidase in this process (Espinosa et al., 2017; Espinosa et al., 2014; Gerson  
81 et al., 1984; Varughese et al., 2018). Patients with chronic granulomatous disease (CGD) and  
82 defective NADPH oxidase function are uniquely vulnerable to invasive aspergillosis (IA, with a  
83 lifetime prevalence of 40-55% (Marciano et al., 2015). Exposure to products of NADPH oxidase  
84 induces a regulated cell death process in conidia trapped within neutrophil phagosomes, resulting  
85 in sterilizing immunity at respiratory mucosal barrier (Shlezinger et al., 2017).

86           An emerging theme of host defense against *Aspergillus* is the essential role of intercellular  
87 crosstalk to license neutrophil effector properties *in situ*. On one hand, recruited monocytes and  
88 Mo-DCs promote neutrophil ROS production through type I and III interferon (IFN) release,  
89 though the link between IFN production and neutrophil ROS activity remains undefined  
90 (Espinosa et al., 2017). On the other hand, we discovered that fungus-engaged neutrophils and  
91 Mo-DCs release CXCL9 and CXCL10 which results in the recruitment of CXCR3<sup>+</sup> pDCs by  
92 promoting their influx from the circulation into the lung. In the lung, pDCs enhance neutrophil  
93 fungicidal properties and are essential for host defense, even in the presence of lung-infiltrating  
94 monocytes and Mo-DCs (Guo et al., 2020). However, the underlying molecular mechanisms that  
95 regulate pDC to neutrophil crosstalk remain undefined. Thus, both Mo-DCs and pDCs  
96 independently enhance neutrophil antifungal activity, but it is unknown whether pDCs employ  
97 either similar or distinct mechanisms of intercellular crosstalk with neutrophils compared to  
98 monocytes and Mo-DCs. Critical open questions relate to the identity of pDC-derived molecules  
99 that are required for protective crosstalk with neutrophils and to the ensuing molecular changes  
100 in neutrophils that regulate antifungal activity *in situ*.

101           In this study, we demonstrate that pDCs represent a key and indispensable source of type  
102 I and type III interferons (IFNs) in the lung during respiratory *A. fumigatus* infection. In turn,  
103 pDC-dependent and IFN-induced STAT1 signaling controls neutrophil *Cybb* expression, which  
104 encodes an essential subunit of the NADPH oxidase complex. Thus, protective pDC to  
105 neutrophil crosstalk primarily harnesses intercellular IFN-STAT1 signaling to calibrate the  
106 synthesis of a critical component of the NADPH oxidase complex, thereby licensing neutrophils  
107 to achieve optimal antifungal activity and promoting sterilizing responses against inhaled mold  
108 spores.

## 109 **Results**

### 110 ***Aspergillus fumigatus* induces pDC activation in the lung.**

111 In response to respiratory fungal infection, pDCs exit the bone marrow (BM), enter the  
112 circulation, and traffic to the lung. To gain an understanding of the pDC activation trajectory  
113 during this infection-induced trafficking event, we conducted an unbiased transcriptome analysis  
114 of BM pDCs isolated from uninfected mice and of BM and lung pDCs isolated from mice at 72 h  
115 post-infection (pi), since this time point represents the peak of lung pDC influx (Fig. 1A, 1B,  
116 Supplemental Fig. S1A). For each pDC RNA-seq sample, we pooled sorted pDCs from 10 mice  
117 from each tissue examined and analyzed 4 biological replicates. The bulk pDC transcriptome  
118 was remarkably similar between naïve and infected BM pDCs, with only 51 differentially  
119 expressed genes, supporting a model in which pDC activation occurs en route to the site of  
120 infection. In these two groups of BM pDCs, we did not observe notable differences in the  
121 transcription of genes that encode cytokines or interferons (Fig. 1C, Supplemental Fig. S1B). In  
122 contrast, RNA-seq analysis revealed significant changes in the pDC transcriptome when lung  
123 pDCs were isolated from *Aspergillus*-infected mice and compared to BM pDCs from the same  
124 animals (Fig. 1B). Overall, pDCs from infected lungs had 4475 and 4474 differentially regulated  
125 genes compared to pDCs isolated from the BM of naïve and infected mice, respectively. (Fig. 1C,  
126 Supplemental Fig. S1C and S1D). Using Kyoto Encyclopedia of Genes and Genomes (KEGG)  
127 pathway enrichment analysis, we found that pathways involved in the cytokine-cytokine receptor  
128 interaction, Toll-like receptor, RIG-I, and JAK-STAT signaling were among the most  
129 upregulated pathways in pDCs isolated from infected lungs compared to BM pDCs isolated from  
130 the same mice (Fig. 1D and Supplemental Fig. S1E).

131 Lung-infiltrating pDCs upregulated genes implicated in fungal recognition, including the  
132 C-type lectin receptors *Clec7a*, *Clec4n*, *Clec4d*, *Clec4e*, *Clec9a*, *Cd69* and *Cd209e* and  
133 downstream signaling molecules (*Card9* and *Syk*). pDCs upregulated Toll-like (*Tlr2*, *Tlr7*, *Tlr9*,  
134 and *Myd88*), and growth factor (*Csf2ra*, *Csf2rb*) signaling pathways as well. Notably, we found  
135 that expression of type I interferon (IFN), type III IFN, and the type I IFN receptor (*Ifnar1* and  
136 *Ifnar2*), were markedly increased in lung-infiltrating pDCs isolated from infected mice (Fig. 1E),  
137 consistent with prior reports that *A. fumigatus* infection induces type I and type III IFN release in  
138 the lung (Espinosa et al., 2017). In addition, lung-infiltrating pDCs upregulated cytokine and  
139 chemokine (*Cxcl9*, *Cxcl10* and *Il12b*), integrin receptor (i.e., *Icam1*, Intercellular Adhesion  
140 Molecule) and *Hif1a* mRNAs (Fig. 1E).

141 To examine the impact of pDC transcriptional changes on protein expression, we infected  
142 IFN- $\beta$  reporter mice with *A. fumigatus* and found that *ifnb* promoter-driven fluorescent protein  
143 expression increased when BM pDCs trafficked to the lung (Fig. 1F and 1H). Similarly, we  
144 observed pDC trafficking-dependent increases in ICAM-1 surface expression (Fig. 1G and 1I).  
145 Thus, *A. fumigatus* infection substantially alters the pDC transcriptome at the portal of infection.

146

#### 147 **pDCs regulate type I and type III IFN in the lung during *A. fumigatus* infection.**

148 To examine the contribution of pDCs to the lung inflammatory milieu, we examined type  
149 I (*Ifna1/2/5/6*) and type III (*Ifnl2/3*) IFN induction and found that induction peaked at 48 to 72  
150 hpi (Fig. 1E and Fig. 2A-2C), temporally coincident with the peak lung pDC influx observed in a  
151 prior study (Guo et al., 2020). To determine whether pDCs directly control type I and type III  
152 induction, we infected BDCA2-DTR (pDC Depletor) mice, in which diphtheria toxin (DT)  
153 administration specifically ablates pDCs at rest and under inflammatory conditions (Swiecki et

154 al., 2010), but does not ablate -CC- chemokine receptor 2 (CCR2)-expressing monocytes and  
155 Mo-DCs that have been implicated in type I and type III IFN release following *A. fumigatus*  
156 infection (Espinosa et al., 2017; Guo et al., 2020). pDC depletor mice exhibited a 60-80%  
157 reduction in lung *Ifna1/2/5/6* and *Ifnl2/3* mRNA levels at 72 hpi, demonstrating that pDCs  
158 directly control the induction of type I and III IFN mRNA, consistent with the bulk RNA-seq  
159 data and with their activation trajectory in the *Aspergillus*-infected lung (Fig. 1E).

160 To measure the importance of pDCs for lung cytokine levels, we next compared lung  
161 cytokine profiles by ELISA from pDC-depleted mice and from non-transgenic, co-housed  
162 littermate controls. pDC ablation resulted in a partial depletion (40-60%) of lung type I (IFN-  
163  $\alpha 2/4$ ) and type III IFN levels (IFN- $\lambda 2/3$ ). In contrast, other pro-inflammatory cytokines  
164 implicated in pulmonary antifungal defense (GM-CSF, TNF, IL-1 $\beta$ , IL-6, and IL-12) were not  
165 impacted by pDC ablation, due to their production by other cellular sources (Mills et al., 2024) in  
166 the lung (Fig. 2E and 2F). These data establish that pDCs play a critical role in regulating lung  
167 type I and type III IFN levels during *A. fumigatus* infection.

168

### 169 **STAT1 signaling in neutrophils controls the intracellular killing of *Aspergillus conidia*.**

170 Type I and type III IFNs both activate STAT1 signaling in target cells and are essential  
171 for host defense against *A. fumigatus* (Espinosa et al., 2017). Under baseline conditions and  
172 during *Aspergillus* infection, lung neutrophils expressed both type I IFN receptor and type III  
173 IFN receptor mRNA, as judged by RNAscope analysis (Supplemental Fig. S2A and S2B), and  
174 both signal through STAT1. Targeted ablation of *Stat1* in neutrophils renders mice susceptible to  
175 invasive aspergillosis, yet it is unknown how STAT1 signaling is coupled to myeloid cell



176 antifungal activity and whether STAT1 signaling is required for killing in a myeloid cell-intrinsic  
177 or -extrinsic manner.

178 To distinguish these possibilities, we generated mixed BM chimeric mice (1:1 mixture of  
179 CD45.2<sup>+</sup> *Stat1*<sup>-/-</sup> and CD45.1<sup>+</sup> *Stat1*<sup>+/+</sup> donor BM cells → lethally irradiated CD45.1<sup>+</sup> CD45.2<sup>+</sup>  
180 *Stat1*<sup>+/+</sup> recipients) and compared the fungicidal activity of *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup> leukocytes within  
181 the same lung inflammatory context (Fig. 3A). To accomplish this, we utilized fluorescent  
182 *Aspergillus* reporter (FLARE) conidia that encode a red fluorescent protein (DsRed; viability  
183 fluorophore) and are labeled with an Alexa Fluor 633 (AF633; tracer fluorophore) (Jhingran et  
184 al., 2016). FLARE conidia enable us to distinguish live (DsRed<sup>+</sup>AF633<sup>+</sup>) and dead (DsRed<sup>-</sup>  
185 AF633<sup>+</sup>) conidia during leukocyte interactions with single encounter resolution (Fig. 3B).

186 Following infection with FLARE conidia, we measured the frequency of neutrophil  
187 fungal uptake (Fig. 3C, frequency of neutrophil uptake = R1 + R2) and the proportion of fungus-  
188 engaged neutrophils that contain live conidia (Fig. 3C, proportion of fungus-engaged neutrophils  
189 with live conidia = R1/ (R1 + R2)). *Stat1*<sup>-/-</sup> neutrophils engulfed conidia at a slightly lower rate  
190 compared to *Stat1*<sup>+/+</sup> neutrophils in the same lung (Fig. 3D). However, the frequency of fungus-  
191 engaged neutrophils that contained live conidia was higher in *Stat1*<sup>-/-</sup> neutrophils compared to  
192 *Stat1*<sup>+/+</sup> neutrophils (Fig. 3E). Thus, neutrophil-engulfed conidia were more likely to be viable in  
193 *Stat1*<sup>-/-</sup> neutrophils than in *Stat1*<sup>+/+</sup> neutrophils in the same lung tissue environment (Fig. 3E),  
194 indicating that STAT1 signaling enhances neutrophil fungicidal activity in a cell-intrinsic  
195 manner. Consistent with these findings and in line with published studies (Espinosa et al., 2017)  
196 we found that mice that lacked *Stat1* in radiosensitive hematopoietic cells were more susceptible  
197 to *A. fumigatus* challenge than mice with *Stat1* sufficiency in the same compartment (Fig. 3F and

198 3G). *Stat1* expression in radiosensitive hematopoietic cells was dispensable for lung IFN- $\alpha$  2/4,  
199 IFN- $\lambda$  2/3, IL-1 $\beta$ , IL-6, IL-12p70, IL-23, and TNF levels (Supplemental Fig. S3A and 3H).

200 Our previous work found that lung pDCs regulate neutrophil ROS generation during  
201 respiratory *A. fumigatus* challenge (Guo et al., 2020). Here we measured neutrophil ROS  
202 production in *Stat1*<sup>+/+</sup> and *Stat1*<sup>-/-</sup> neutrophils and found that the ROS median fluorescence  
203 intensity (MFI) in *Stat1*<sup>-/-</sup> ROS<sup>+</sup> lung neutrophils were significantly reduced compared *Stat1*<sup>+/+</sup>  
204 ROS<sup>+</sup> lung neutrophils at 72 hpi (Fig. 3I and 3J). We enumerated myeloid cells infiltration in  
205 *Stat1*<sup>+/+</sup> and *Stat1*<sup>-/-</sup> lungs at 72 hpi, and found no difference in the recruitment of neutrophils,  
206 monocyte, and pDCs in *Stat1*<sup>-/-</sup> mice. There was a slight decrease in Mo-DC numbers in *Stat1*<sup>-/-</sup>  
207 mice, which suggests that monocytes may exhibit a limited differentiation into Mo-DCs,  
208 resulting in reduced lung Mo-DC numbers in *Stat1*<sup>-/-</sup> mice compared to control mice (Fig. S3B-  
209 S3E).

210

### 211 **pDCs regulate neutrophil STAT1-dependent antifungal activity.**

212 To explore whether pDCs regulate neutrophil STAT1-dependent antifungal activity, we  
213 bred CD45.2<sup>+</sup> BDCA2-DTR<sup>Tg/+</sup> mice with CD45.2<sup>+</sup> *Stat1*<sup>-/-</sup> mice to generate CD45.2<sup>+</sup> BDCA2-  
214 DTR<sup>Tg/+</sup> *Stat1*<sup>-/-</sup> mice and bred BDCA2-DTR<sup>Tg/+</sup> *Stat1*<sup>+/+</sup> mice to the CD45.1<sup>+</sup> (C57BL6.SJL)  
215 background. BM cells from both strains were mixed in a 1:1 ratio and utilized as donor cells to  
216 generate mixed BM chimeric mice (CD45.1<sup>+</sup> BDCA2-DTR<sup>Tg/+</sup> *Stat1*<sup>+/+</sup> and CD45.2<sup>+</sup> BDCA2-  
217 DTR<sup>Tg/+</sup> *Stat1*<sup>-/-</sup> → CD45.1<sup>+</sup>CD45.2<sup>+</sup> recipient mice). This experimental design enabled us to  
218 compare the fungicidal activity of *Stat1*<sup>+/+</sup> and *Stat1*<sup>-/-</sup> neutrophils in the same lung, either in the  
219 absence or in the presence of pDCs through the administration or omission of DT to mixed BM  
220 chimeric mice (Fig. 4A).

221 This experimental approach yielded 4 groups of neutrophils that were analyzed 72 hpi  
222 with FLARE conidia. Group 1 (G1) neutrophils were *Stat1*<sup>+/+</sup> neutrophils isolated from pDC-  
223 sufficient mice; G2 neutrophils were *Stat1*<sup>+/+</sup> neutrophils isolated from pDC-ablated mice; G3  
224 neutrophils were *Stat1*<sup>-/-</sup> neutrophils isolated from pDC-sufficient mice; and G4 neutrophils were  
225 *Stat1*<sup>-/-</sup> neutrophils isolated from pDC-ablated mice (Fig. 4A). There was no difference in  
226 conidial uptake among these four groups of neutrophils (Fig. 4B and 4C), indicating that pDCs  
227 do not control neutrophil conidial uptake and that neutrophil-intrinsic STAT1 signaling is  
228 dispensable for this process.

229 The frequency of neutrophils that contained live conidia was markedly increased in G3  
230 (pDC<sup>+</sup> lungs; *Stat1*<sup>-/-</sup>) neutrophils compared to G1 (pDC<sup>+</sup> lungs; *Stat1*<sup>+/+</sup>) neutrophils (Fig. 4B  
231 and 4D), consistent with prior experimental results (Fig. 3E). Critically, pDC ablation increased  
232 the frequency of *Stat1*<sup>+/+</sup> neutrophils that contained live conidia (comparison of G2 versus G1  
233 neutrophils; P = 0.027, Fig. 4B and 4D). This result indicates that pDC-derived products  
234 contribute to STAT1-dependent neutrophil conidiacidal activity. In contrast, pDC ablation did  
235 not significantly increase the frequency of *Stat1*<sup>-/-</sup> neutrophils that contained live conidia  
236 (comparison of G4 versus G3 neutrophils; P = 0.09, Fig. 4B and 4D).

237 To obtain a complementary measurement of pDC to neutrophil STAT1 crosstalk, we  
238 measured ROS production in the 4 neutrophil groups in parallel. Consistent with the direct  
239 measurements of fungicidal activity in Fig. 4D and with the ROS measurements in Fig. 3I and 3J,  
240 *Stat1*<sup>+/+</sup> neutrophils displayed a higher ROS mean fluorescence intensity (MFI) than *Stat1*<sup>-/-</sup>  
241 neutrophils (G1 versus G3). pDC ablation markedly reduced ROS production by *Stat1*<sup>+/+</sup>  
242 neutrophils (G2 versus G1), in line with the reduction in neutrophil fungicidal activity (Fig. 4E).  
243 In fact, *Stat1*<sup>+/+</sup> neutrophils isolated from pDC-depleted lungs (G2) had a similar ROS MFI as

244 *Stat1*<sup>-/-</sup> neutrophils isolated from pDC-sufficient lungs (G3). ROS levels observed in *Stat1*<sup>-/-</sup>  
245 neutrophils isolated from pDC-depleted lungs (G3) was lower than the ROS levels observed in  
246 *Stat1*<sup>-/-</sup> neutrophils isolated from pDC-sufficient lungs (Fig. 4E), consistent with the idea that  
247 pDCs can further modulate neutrophil ROS production in a *Stat1*-independent fashion.  
248 Collectively, these findings indicate that pDCs regulate STAT1-dependent neutrophil fungicidal  
249 activity and ROS production.

250

251 **STAT1-dependent guanylate-binding proteins are dispensable for the neutrophil anti-**  
252 **fungus activity.**

253 To gain further insight into how STAT1 regulates cell-intrinsic neutrophil fungicidal  
254 activity and ROS generation during respiratory *A. fumigatus* challenge, we generated mixed bone  
255 marrow chimeric mice (1:1 mix of CD45.2<sup>+</sup> *Stat1*<sup>-/-</sup> and CD45.1<sup>+</sup> *Stat1*<sup>+/+</sup> donor bone marrow  
256 cells → lethally irradiated CD45.1<sup>+</sup>CD45.2<sup>+</sup> *Stat1*<sup>+/+</sup> recipient mice) and performed bulk RNA-  
257 seq on *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup> neutrophils sorted from *A. fumigatus*-infected recipient mice. There  
258 were marked differences in the transcriptome of *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup> lung neutrophils (Fig. 5A),  
259 with 2586 genes showing differential expression in *Stat1*<sup>-/-</sup> neutrophils compared to *Stat1*<sup>+/+</sup>  
260 neutrophils. KEGG pathway enrichment analysis showed downregulation of many pathways in  
261 *Stat1*<sup>-/-</sup> neutrophils, including the cytosolic DNA sensing pathway, proteasome, RIG-I like  
262 receptor signaling pathway, Toll-like receptor signaling pathway, cytokine-cytokine receptor  
263 pathway (Fig. 5B). We identified commonly downregulated genes in *Stat1*<sup>-/-</sup> neutrophils, many  
264 of which were known interferon-regulated genes (ISGs; Fig. 5C).

265 Several GTPases guanylate-binding proteins (GBPs), including *Gbp2*, *Gbp3*, *Gbp5* and  
266 *Gbp7* were significantly downregulated in *Stat1*<sup>-/-</sup> neutrophils (Fig. 5C). To address the function

267 of these genes in neutrophil antifungal activity in otherwise immune competent mice, we utilized  
268  $Gbp^{chr3-/-}$  mice, which lack the entire chromosome 3 cluster that contains *Gbp1*, *Gbp2*, *Gbp3*,  
269 and *Gbp5*. We generated single chimeric mice ( $CD45.2^+ Gbp^{chr3-/-}$  or  $CD45.2^+ Gbp^{chr3+/+}$  →  
270 lethally irradiated  $CD45.1^+ Gbp^{chr3+/+}$  recipients) (Fig. 5D) and compared the mortality and  
271 fungal burden of  $Gbp^{chr3-/-}$  and  $Gbp^{chr3+/+}$  chimeric mice. As expected from a prior study in  
272 corticosteroid and cyclophosphamide-treated mice (Briard et al., 2019), there was no difference  
273 in mortality or fungal colony forming unit (CFU) between  $Gbp^{chr3-/-}$  and  $Gbp^{chr3+/+}$  chimeric  
274 mice (Fig. 5E and 5F). Using mixed chimeric mice ( $CD45.2^+ Gbp^{chr3-/-}$  and  $CD45.1^+ Gbp^{chr3+/+}$   
275 →  $CD45.1^+ CD45.2^+ Gbp^{chr3+/+}$  recipients) (Fig. 5G) and FLARE conidia, we quantified the cell-  
276 intrinsic antifungal activity of  $Gbp^{chr3-/-}$  and  $Gbp^{chr3+/+}$  leukocytes and found no difference in  
277 neutrophil conidial uptake and killing (Fig. 5H and 5I). Moreover,  $Gbp^{chr3-/-}$  and  $Gbp^{chr3+/+}$   
278 neutrophils isolated from the same lung exhibited no difference in ROS MFI (Fig. 5J).

279

## 280 **The pDC-IFN-STAT1 axis regulates neutrophil *Cybb* expression during *A. fumigatus*** 281 **infection.**

282 Since GBPs did not contribute to STAT1-regulated neutrophil defense against *A.*  
283 *fumigatus*, we investigated other candidate genes that were downregulated in *Stat1<sup>-/-</sup>* neutrophils  
284 (Fig. 5C) and focused next on *Cybb*, which encodes CYBB, the p91 subunit of the NADPH  
285 oxidase complex (NOX2). The four genes (*Cyba*, *Ncf1*, *Ncf2*, and *Ncf4*) that encode other  
286 subunits of the neutrophil NADPH oxidase complex (CYBA/p22 subunit, NCF1/p47 subunit,  
287 NCF2/p67 subunit and NCF4/p40 subunit) were not downregulated in *Stat1<sup>-/-</sup>* neutrophils (Fig.  
288 6A). During *A. fumigatus* infection lung *Cybb* expression peaked at 48 and 72 hpi (Fig. S4A),  
289 temporally coincident with the observed peaks in lung pDC influx and type I and type III IFN

290 expression (Fig. 2A-C). The production of reactive oxygen species (ROS) by neutrophils is a  
291 vital mechanism for effectively eradicating fungal infections. Consistent with a prior study, we  
292 confirmed that *Cybb*-deficient mice (*gp91<sup>phox-/-</sup>*) were highly susceptible to *A. fumigatus* infection  
293 (Fig. S4B) (Pollock et al., 1995). To investigate the hypothesis that STAT1 signaling in  
294 neutrophils regulates *Cybb* expression, we isolated neutrophils from infected *Stat1<sup>-/-</sup>* and *Stat1<sup>+/+</sup>*  
295 mice and found that *Cybb* mRNA level were decreased in *Stat1<sup>-/-</sup>* neutrophils compare to *Stat1<sup>+/+</sup>*  
296 neutrophils (Fig. 6B), consistent with STAT1-dependent regulation of *Cybb* transcription.

297 To determine chromatin accessibility at the *Cybb* locus, we performed assay for  
298 transposase-accessible chromatin (ATAC) sequencing of sorted *Stat1<sup>-/-</sup>* and *Stat1<sup>+/+</sup>* lung  
299 neutrophils from *A. fumigatus*-infected mice. Within the *Cybb* locus, we found three regions  
300 (blue squares) that were less accessible in *Stat1<sup>-/-</sup>* neutrophils than in *Stat1<sup>+/+</sup>* neutrophils (Fig.  
301 6C), consistent with a modest STAT1-dependent regulation of *Cybb* expression (Fig. 6A and 6B).  
302 As a positive control, within *Gbp2* locus, we found one region (red square) that was less  
303 accessible in *Stat1<sup>-/-</sup>* neutrophils compared to *Stat1<sup>+/+</sup>* neutrophils (Fig. 6C), consistent with  
304 STAT1-dependent regulation of *Gbp* expression (Fig. 5C).

305 To probe STAT1 binding to the *Cybb* gene locus, we performed Cleavage Under Targets  
306 & Release Using Nuclease (CUT&RUN) experiments of sorted *Stat1<sup>-/-</sup>* and *Stat1<sup>+/+</sup>* lung  
307 neutrophils from *A. fumigatus*-infected mice. We did not observe direct STAT1 binding to *Cybb*  
308 locus and promoter region (Fig. 6D). In CUT&RUN experiments, STAT1 bound to the *Gbp2*  
309 locus and promoter region (Fig. 6D). Collectively, these results suggest that STAT1 regulates  
310 *Cybb* transcription via an indirect mechanism.

311 Because STAT1 did not appear to regulate *Cybb* transcription through direct effects on  
312 chromosomal accessibility or binding to the *Cybb* locus, we next explored whether lung

313 neutrophil CYBB protein levels were regulated by STAT1 signaling. *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup>  
314 neutrophils were isolated from *A. fumigatus* infected mice lungs at 72 hpi and analyzed for  
315 CYBB expression by Western blotting. CYBB protein levels, but not other subunits (p22/CYBA  
316 and p40/NCF4) of NADPH oxidase protein levels were lower in *Stat1*<sup>-/-</sup> neutrophils compared to  
317 *Stat1*<sup>+/+</sup> neutrophils (Fig. 6E – 6H), linking neutrophil STAT1 activation to CYBB expression,  
318 and to the oxidative burst.

319

## 320 **Discussion**

321 Our data introduce a model of protective pDC to neutrophil crosstalk in which pDCs  
322 undergo a defined activation trajectory in transit to the *Aspergillus*-infected lung. pDC activation  
323 provides a critical source of type I and type III IFN at the portal of infection, and licenses  
324 neutrophil antifungal properties in the lung in a direct manner. The latter step occurs through  
325 neutrophil-intrinsic STAT1-dependent control of CYBB protein levels. Local pDC-dependent  
326 control of NADPH oxidase assembly regulates the strength of neutrophil oxidative burst, as  
327 judged by reactive oxygen species production, boosts neutrophil intracellular conidial killing,  
328 and confers sterilizing immunity against inhaled spores.

329 pDCs originate in the bone marrow (BM), travel through the bloodstream, and migrate to  
330 lymphoid and nonlymphoid tissues during both normal and inflammatory states (Fujimura et al.,  
331 2015; Guo et al., 2020; Sozzani et al., 2010; Swiecki et al., 2017). In a recent study we  
332 demonstrated that *Aspergillus*-infected Mo-DCs and neutrophils release CXCR3 ligands (i.e.,  
333 CXCL9 and CXCL10) into the inflamed lung, coupling fungal recognition and fungus-induced  
334 inflammation to CXCR3 signaling-dependent pDC influx from the circulation into the lung. In  
335 this study, *A. fumigatus* infection induces a pDC activation trajectory that substantially alters the

336 lung rather than the BM pDC transcriptome, implying that pDC trafficking to peripheral tissue  
337 precedes activation occurs at the portal of infection. While not a focus of this work, the precise  
338 mechanism of pDC activation in the fungus-infected lung remains an open question, in part  
339 because conditional gene deletion strategies do not exist for pDCs, precluding facile comparison  
340 of gene-deficient and gene-sufficient pDCs in infected tissues in mice with no other genetic  
341 perturbations.

342 Our data indicate that lung-infiltrating pDCs upregulate genes implicated in fungal  
343 recognition, including the C-type lectin receptors (CLRs) and downstream signaling molecules.  
344 pDCs express the C-type lectin receptors Dectin-1, Dectin-2, and Dectin-3 and can secrete IFN-  
345  $\alpha$  and TNF when co-incubated with *Aspergillus* hyphae via Dectin-2 signaling (Maldonado et al.,  
346 2022; Seeds et al., 2009; Taylor et al., 2002), though the interaction of pDCs with conidia, the  
347 infectious propagules, were not examined. pDCs do not internalize *Aspergillus* conidia readily in  
348 the test tube or in the infected lung (Desai et al., 2024; Maldonado et al., 2022), supporting the  
349 notion that activation occurs via fungal cell contact or via the presence of activating cytokines or  
350 other inflammatory mediators. Support for the latter scenario comes from an experiment in  
351 which curdlan (i.e., a particulate Dectin-1 agonist)-induced upregulation of pDC CD40 and  
352 CD83 expression could be increased by simultaneous co-incubation with an acellular curdlan-  
353 stimulated peripheral blood mononuclear cell supernatant (Maldonado et al., 2022). Beyond  
354 *Aspergillus*, pDC-enriched human cell fractions can release TNF in a Dectin-2- and Dectin-3-  
355 signaling-dependent fashion in response to *Paracoccidioides brasiliensis* co-incubation (Preite et  
356 al., 2018). Beyond CLR signaling, we found that *Aspergillus* infection triggered upregulation of  
357 Toll-like receptors in lung-infiltrating pDCs. Prior work demonstrated that *Aspergillus*-derived  
358 unmethylated CpG sequences can activate TLR9 signaling *in vitro* (Herbst et al., 2015; Ramirez-



359 Ortiz et al., 2008), and this may represent an additional mechanism by which pDCs become  
360 activated *during Aspergillus* infection.

361         During Dengue, Zika, and Hepatitis C viral infections, physical contact with virally  
362 infected cells stimulates pDC-mediated antiviral responses (Assil et al., 2019; Webster et al.,  
363 2018).  $\alpha_1\beta_2$  integrin (lymphocyte function-associated antigen-1; LFA-1) expressed by the pDC  
364 can bind to ICAM-1 on infected cells to promote a sustained interaction, termed an  
365 interferonogenic synapse, during which viral RNA is transferred to pDCs, leading to IFN  
366 production via the nucleic acid sensor TLR7. This process activates type I IFN-dependent  
367 antiviral programs in infected tissues. pDC commitment to type I IFN production is further  
368 regulated by antecedent cell-intrinsic TNF receptor and leukemia inhibitory factor signaling  
369 during murine cytomegalovirus infection, underscoring the contribution of local cytokine  
370 signaling to pDC activation by contact-dependent and -independent mechanisms (Abbas et al.,  
371 2020). The lung pDC transcriptomic data detected increased expressed ICAM-1 in the lung-  
372 infiltrating pDCs isolated from infected mice. This observation raises the possibility that ICAM-  
373 1 expression may facilitate lung pDC contact with  $\beta_2$ -integrin-expressing myeloid cells to  
374 facilitate reciprocal interactions. In sum, the upregulation of multiple receptors from various  
375 classes suggests that pDCs likely employ a blend of receptors to identify and react to fungal  
376 pathogens, leading to full pDC activation in the fungus-infected lung. Notably, we were unable  
377 to isolate sufficient pDCs to compare the bulk lung pDC transcriptome in naïve mice with the  
378 lung pDC transcriptome in *Aspergillus*-infected mice.

379         Recent studies have advanced the concept that circulating neutrophils exhibit  
380 transcriptional heterogeneity in the steady state and during microbial infection (Xie et al., 2020).  
381 In addition, neutrophils can acquire transcription-dependent non-canonical functions upon entry

382 into peripheral tissues, exemplified by a regulatory role in angiogenesis in the lung (Ballesteros  
383 et al., 2020). Single-cell analysis has revealed the presence of three separate circulating murine  
384 and human populations that differ with respect to interferon-stimulated gene (ISG) and CXCR4  
385 expression. Interestingly, all three populations expressed similar levels of *Cybb* mRNA and  
386 exhibited similar NADPH oxidase scores by gene ontology analysis during homeostasis and  
387 systemic bacterial (i.e., *Escherichia coli*) infection (Xie et al., 2020). During tuberculosis,  
388 malaria, and hematopoietic cell transplantation, circulating human neutrophils exhibit an IFN  
389 transcriptional signature (Berry et al., 2010; Montaldo et al., 2022; Rocha et al., 2015), which in  
390 the case of malaria, is reduced by receipt of anti-malarial therapy. The finding that pDC-derived  
391 type I and type III IFN licenses neutrophil antifungal activity through STAT1-dependent control  
392 of *Cybb* transcription and CYBB protein levels raises the important question whether the ISG<sup>hi</sup>  
393 neutrophil subset is enriched in the lung and particularly effective at killing *Aspergillus* conidia  
394 compared to the other two ISG<sup>lo</sup> circulating subsets. The ability to track and quantify fungal  
395 uptake killing with FLARE conidia will facilitate future studies to link lung-infiltrating  
396 neutrophil subsets, defined by distinct transcriptional profiles, to the quality of effector functions  
397 at single-encounter resolution. These studies support idea that dynamic transcriptional plasticity  
398 represents a cardinal feature of the circulating neutrophil response to microbial infection and  
399 other external stressors. It remains unclear whether the observed transcriptional plasticity  
400 represents dynamic changes in the production of transcriptionally heterogeneous circulating  
401 neutrophil subsets or represents an interconversion between circulating subsets.

402         The effects of type III IFN on neutrophils are context-dependent. In a DSS model of  
403 sterile colitis, IFN- $\lambda$  has been linked to neutrophil ROS suppression and a reduction in  
404 neutrophil degranulation (Broggi et al., 2017). In human neutrophils, recombinant IFN- $\lambda$  can

405 inhibit platelet-induced NETosis (Chrysanthopoulou et al., 2017). IFN- $\lambda$  has various roles in  
406 bacterial infections (Ardanuy et al., 2020; Lazear et al., 2015), with a previous study  
407 demonstrated that *Bordetella pertussis* infection induces IFN- $\lambda$  and IFN- $\lambda$  receptor (IFNLR1)  
408 expression as well as inflammation in the lung (Ardanuy et al., 2020). IFN- $\lambda$  signaling in  
409 neutrophils can suppress *B. pertussis* killing and neutrophil production of ROS, MMP9, NETs,  
410 MPO, and IFN- $\gamma$  (Antos et al., 2024; Kumar et al., 2024). In contrast, conditional deletion of the  
411 IFN- $\lambda$  receptor in neutrophils is linked to a reduction in neutrophil ROS during pulmonary *A.*  
412 *fumigatus* infection (Espinosa et al., 2017). During HSV corneal infection, application of  
413 recombinant IFN- $\lambda$  suppressed neutrophil recruitment but did not impact virucidal activity or  
414 ROS production (Antony et al., 2021). These results indicate that IFN- $\lambda$  may have different  
415 biological effects based on cellular targets and responsiveness at sites of inflammation and on the  
416 type of inflammatory stimulus. In this study, the STAT1-dependent action of pDC-dependent  
417 IFNs (both type I and III) on neutrophils is critical for their local licensing of their cell-intrinsic  
418 cytotoxic activity against *Aspergillus* conidia. The individual contribution of type I versus type  
419 III IFN-dependent activation on STAT1-dependent CYBB expression remains unclear. An open  
420 question remains how STAT1 signaling precisely regulates *Cybb* transcription and CYBB  
421 translation, since we could not detect clear evidence of STAT1 binding to the *Cybb* promoter or  
422 clear STAT1-dependent changes in chromatin accessibility.

423 Overall, these findings provide important insights into the pDC-STAT1-CYBB axis as a  
424 key regulator of NADPH oxidase expression and highlight the critical role of this pathway in  
425 promoting antifungal immunity in neutrophils. The discovery that pDCs can regulate ROS  
426 induction by neutrophils by controlling the STAT1-dependent expression of a single NADPH

427 oxidase subunit adds to our understanding of the complex and protective interplay between  
428 innate immune cells during fungal infection.

429

## 430 **ACKNOWLEDGMENTS**

431 We thank Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital)  
432 providing the *GBP<sup>chr3-/-</sup>* bone marrows. We thank the MSKCC IGO core for performing RNA  
433 sequencing, and Chen Liao (Geisel School of Medicine at Dartmouth), Paul Zumbo (Weill  
434 Cornell Medicine) for assistance with the RNA sequencing data analysis. We thank Robert  
435 Cramer (Geisel School of Medicine at Dartmouth), Iliyan Iliev (Weill Cornell Medicine), and  
436 members of the Hohl laboratory for numerous conversations and insights into this study. In this  
437 study, T. M. H. was supported by NIH grants P30 CA 008748 (to MSKCC), R37 AI093808, and  
438 R01 AI139632; Y. G. was supported by the Ludwig Center Post-Doctoral Award, MSKCC;  
439 M.A.A. was supported by NIH F31 AI161996; K.A.M.M. was supported by NIH F31 AI167511;  
440 K. B. M. was supported by Experimental Immuno-oncology Scholars' Program, MSKCC and  
441 NIH 5T32CA009149; J. C. S. was supported by the Ludwig Center for Cancer Immunotherapy,  
442 the American Cancer Society, the Burroughs Wellcome Fund, and the NIH grants R01 AI100874,  
443 R01 AI130043, R01 AI155558, and P30CA008748. S. G. was supported by CRI / Donald J.  
444 Gogel Postdoctoral Fellowship CRI Award CRI3934 and NIH K99AI180360. The funders had  
445 no role in study design, data collection and analysis, decision to publish or preparation of  
446 manuscript. We acknowledge the use of the Integrated Genomics Operation Core, funded by the  
447 NCI Cancer Center Support Grant (CCSG, P30 CA08748), Cycle for Survival, and the Marie-  
448 Josée and Henry R. Kravis Center for Molecular Oncology.

449

450

## 451 **AUTHOR CONTRIBUTIONS**

452 Conceptualization, T.M.H., and Y.G.; Methodology, T.M.H., and Y.G.; Investigation, Y.G.,  
453 M.A.A., K.A.M.M, S. A. G., H. K., P. Z., M.G., A.B., K.M., Y. Y.; Writing – Original Draft,  
454 Y.G. and T.M.H.; Writing – Review & Editing, Y.G. and T.M.H.; Funding Acquisition, T.M.H.  
455 and Y.G.; Resources, J. S., and D. B.

456

## 457 **DECLARATION OF INTERESTS**

458 The authors declare no competing interests.

459

## 460 **MATERIALS AND METHODS**

### 461 **Chemicals and reagents**

462 Unless otherwise noted, chemicals were purchased from Sigma-Aldrich or Fisher  
463 Scientific, cell culture reagents from Thermo Fisher Scientific, and microbiological culture  
464 media from BD Biosciences. Antibodies for flow cytometry were acquired from BD Biosciences,  
465 Thermo Fisher Scientific and Tonbo.

466

### 467 **Mice**

468 C57BL/6J (JAX: 00664), BDCA2-DTR (JAX: 014176) mice were from Jackson  
469 Laboratories. *GBP<sup>chr3-/-</sup>* bone marrows were provided by Dr. Thirumala-Devi Kanneganti.  
470 C57BL/6.SJL (Stock: 4007) were purchased from Taconic. C57BL/6 and C57BL/6.SJL mice  
471 were crossed to generate CD45.1<sup>+</sup>CD45.2<sup>+</sup> recipient mice for mixed BM chimeras. CD45.2<sup>+</sup>  
472 BDCA2-DTR<sup>Tg/+</sup> were backcrossed to C57BL/6.SJL mice to obtain CD45.1<sup>+</sup> BDCA2- DTR<sup>Tg/+</sup>

473 mice. BDCA2- DTR<sup>Tg/+</sup> were crossed with CD45. 2<sup>+</sup> *Stat1*<sup>-/-</sup> mice to obtain CD45. 2<sup>+</sup> BDCA2-  
474 DTR<sup>Tg/+</sup> *Stat1*<sup>-/-</sup> mice. For experiments in which the breeding strategy did not yield littermate  
475 controls, gene-knockout mice were co-housed with C57BL/6 mice for 14 days prior to infection,  
476 whenever possible. All mouse strains were bred and housed in the MSKCC or St. Jude  
477 Children's Research Hospital Animal Resource Center under specific pathogen-free conditions.  
478 All animal experiments were conducted with sex- and age-matched mice and performed with  
479 MSKCC Institutional Animal Care and Use Committee approval. Animal studies complied with  
480 all applicable provisions established by the Animal Welfare Act and the Public Health Services  
481 Policy on the Humane Care and Use of Laboratory Animals.

482

#### 483 **Generation of Bone Marrow Chimeric Mice**

484 For single BM chimeras, CD45.1<sup>+</sup> C57BL/6.SJL recipients were lethally irradiated  
485 (900cGy), reconstituted with either  $2-5 \times 10^6$  CD45.2<sup>+</sup> *GBP*<sup>chr3-/-</sup>, CD45.2<sup>+</sup> C57BL/6J or CD45.2<sup>+</sup>  
486 *Stat1*<sup>-/-</sup> BM cells. For mixed BM chimeras, CD45.1<sup>+</sup>CD45.2<sup>+</sup> recipients were irradiated and  
487 reconstituted with a 1:1 mixture of CD45.1<sup>+</sup> C57BL/6.SJL and CD45.2<sup>+</sup> *Stat1*<sup>-/-</sup> or CD45.2<sup>+</sup>  
488 *GBP*<sup>chr3-/-</sup> BM cells, CD45.1<sup>+</sup> BDCA2- DTR<sup>Tg/+</sup> and CD45.2<sup>+</sup> BDCA2- DTR<sup>Tg/+</sup> *Stat1*<sup>-/-</sup>. After  
489 BM transplantation, recipient mice received 400 µg/ml enrofloxacin in the drinking water for 21  
490 days to prevent bacterial infections and rested for 6-8 weeks prior to experimental use.

491

#### 492 ***Aspergillus fumigatus* Infection Model**

493 *A. fumigatus* Af293, Af293-dsRed (Jhingran et al., 2016), and CEA10 (Girardin et al.,  
494 1993) strains were cultured on glucose minimal medium slants at 37°C for 4-7 days prior to  
495 harvesting conidia for experimental use. To generate FLARE conidia, briefly,  $7 \times 10^8$  Af293-

496 dsRed conidia were rotated in 10 µg/ml Biotin XX, SSE in 1 ml of 50 mM carbonate buffer (pH  
497 8.3) for 2 hr at 4 °C, incubated with 20 µg/ml Alexa Fluor 633 succinimidyl ester at 37 °C for 1  
498 h, resuspended in PBS and 0.025% Tween 20 for use within 24 hrs. (Heung et al., 2015; Jhingran  
499 et al., 2016). To generate morphologically uniform heat-killed swollen conidia,  $5 \times 10^6$ /ml  
500 conidia were incubated at 37° C for 14 hours in RPMI-1640 and 0.5 µg/ml voriconazole and heat  
501 killed at 100 °C for 30 minutes (Hohl et al., 2005). To infect mice with 30-60 million live or  
502 heat-killed *A. fumigatus* cells, conidia were resuspended in PBS, 0.025% Tween-20 at a  
503 concentration of  $0.6-1.2 \times 10^9$  cells and 50 µl of cell suspension was administered via the  
504 intranasal route to mice anesthetized by isoflurane inhalation.

505

#### 506 **Analysis of *in vivo* and *in vitro* conidial uptake and killing**

507 To analyze of conidia uptake and killing, FLARE conidia were used to infect mice. In  
508 data analyses for a given leukocyte subset, conidial uptake refers to the frequency of fungus-  
509 engaged leukocytes, i.e., the sum of dsRed<sup>+</sup> AF633<sup>+</sup> and dsRed<sup>-</sup> AF633<sup>+</sup> leukocytes. Conidial  
510 viability within a specific leukocyte subset refers to the frequency of leukocytes that contain live  
511 conidia (dsRed<sup>+</sup> AF633<sup>+</sup>) divided by the frequency of all fungus-engaged leukocytes (dsRed<sup>+</sup>  
512 AF633<sup>+</sup> and dsRed<sup>-</sup> AF633<sup>+</sup>).

513

#### 514 ***In vivo* Cell Depletion**

515 To ablate specific cells, BDCA2- DTR<sup>Tg/+</sup>, BDCA2- DTR<sup>Tg/+</sup> *Stat1*<sup>-/-</sup>, and non-transgenic  
516 littermate controls were injected i.p. with 10 ng/g body weight DT on Day -1, Day 0, and Day +2  
517 pi (Swiecki et al., 2010), unless noted otherwise.

518

519

## 520 **Analysis of Infected Mice**

521 To prepare single cell lung suspensions for flow cytometry, we followed the method  
522 outlined in (Hohl et al., 2009) with minor modifications. After perfusing murine lungs, they were  
523 placed in a gentle MACS™ C tube and mechanically homogenized in 5 ml RPMI-1640, 10%  
524 FBS, and 0.1 mg/ml DNase using a gentle MACS™ Octo Dissociator (Miltenyi Biotech)  
525 without the use of collagenase. The lung cell suspensions were then lysed of RBCs, enumerated,  
526 and stained with fluorophore-conjugated antibodies prior to flow cytometric analysis. We used  
527 either a Cytoflex or a BD Aria for flow cytometric sorting and performed flow plot analysis  
528 using FlowJo v.9.6.6 software.

529 Neutrophils were identified as  $CD45^+ CD11b^+ Ly6C^{lo} Ly6G^+$  cells, monocytes as  
530  $CD45^+ CD11b^+ CD11c^- Ly6G^- Ly6C^{hi}$  cells, Mo-DCs as  $CD45^+ CD11b^+ CD11c^+ Ly6G^-$   
531  $Ly6C^{hi} MHC\ class\ II^+$  cells, and pDCs as  $CD45^+ CD11c^{int} SiglecF^- CD19^- NK1.1^- CD11b^-$   
532  $B220^+ SiglecH^+$  cells.

533 To assess the lung fungal burden, perfused murine lungs were homogenized using a  
534 PowerGen 125 homogenizer (Fisher) in 2 mL of PBS containing 0.025% Tween-20 and plated  
535 onto Sabouraud dextrose agar. For analysis of cytokine levels by ELISA, whole lungs were  
536 weighed and mechanically homogenized in 2 mL of PBS containing protease inhibitors. To  
537 analyze cytokine levels by qRT-PCR, we extracted total RNA from cells using TRIzol  
538 (Invitrogen). One to two micrograms of total RNA were reverse-transcribed using the High-  
539 Capacity cDNA Reverse Transcription Kit (Applied Biosystems). We used TaqMan Fast  
540 Universal Master Mix (2×) and TaqMan probes (Applied Biosystems) for each gene and



541 normalized to glyceraldehyde-3-phosphate dehydrogenase. Gene expression was calculated  
542 using the Ct method relative to the naïve sample.

543 Intracellular ROS levels were measured in cells using CM-H2DCFDA [5-(and 6-)  
544 chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester] as described in (Hackstein  
545 et al., 2012). Briefly, single cell lung suspensions were incubated with 1µM CM-H2DCFDA in  
546 Hanks' balanced salt solution at 37° C for 45 min according to manufacturer's instruction and  
547 analyzed by flow cytometry.

548

#### 549 **Immunoblotting assay**

550 Cells were lysed in lysis buffer (150 mM NaCl, 50 mM HEPES (pH 7.4), 1 mM EDTA, 1%  
551 Nonidet P-40, protease inhibitors). Total cell lysates were subjected to SDS-PAGE and then  
552 blotted using indicated antibodies, Cybb polyclonal antibody (Invitrogen, cat. no. PA5-76034),  
553 p22phox mAb (CST, cat. no. 37570), p40phox mAb (cat. no. AB76158), GAPDH mAb (CST,  
554 cat. no. 5174s).

555

#### 556 **RNA sequencing**

557 **RNA extraction.** Phase separation in cells lysed in 1 mL TRIzol Reagent (ThermoFisher cat. no.  
558 15596018) was induced with 200 µL chloroform. RNA was extracted from 350 µL of the  
559 aqueous phase using the miRNeasy Micro or Mini Kit (Qiagen cat. no. 217084/217004) on the  
560 QIAcube Connect (Qiagen) according to the manufacturer's protocol. Samples were eluted in  
561 13-15 µL RNase-free water.

562

563 **Transcriptome sequencing.** After RiboGreen quantification and quality control by Agilent  
564 BioAnalyzer, 1.9-2.0 ng total RNA with RNA integrity numbers ranging from 7.8 to 10  
565 underwent amplification using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech cat. no.  
566 63488), with 12 cycles of amplification. Subsequently, 7.4-10 ng of amplified cDNA was used to  
567 prepare libraries with the KAPA Hyper Prep Kit (Kapa Biosystems cat. no. KK8504) using 8  
568 cycles of PCR. Samples were barcoded and run on a HiSeq 4000 or NovaSeq 6000 in a PE50  
569 (HiSeq) or PE100 (NovaSeq) run, using the HiSeq 3000/4000 SBS Kit or NovaSeq 6000 S4  
570 Reagent Kit (200 Cycles) (Illumina). An average of 40 million paired reads were generated per  
571 sample and the percent of mRNA bases per sample averaged 84%.

572

573 **RNA-Sequencing data analysis.** Raw reads were quality checked with FastQC v0.11.7  
574 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), and adapters were trimmed using  
575 Trim Galore v0.6.7 ([http://www.bioinformatics.babraham.ac.uk/projects/trim\\_galore/](http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)). Reads  
576 were aligned to the mouse reference genome (GRCm38.p6) using STAR v2.6.0c (Dobin et al.,  
577 2013) with default parameters. Gene abundances were calculated with featureCounts v1.6.2  
578 (Liao et al., 2014) using composite gene models from Gencode release vM17 . Principle  
579 component analysis was performed using the plotPCA function from DESeq2 v1.32.0 (Love et  
580 al., 2014). Differentially expressed genes were determined with DESeq2 v1.32.0 with a two-  
581 factor model incorporating batch as a covariate, with significance determined by Wald tests ( $q <$   
582  $0.05$ ). Gene set enrichment analysis was performed using fgsea v1.18.0 (Korotkevich et al., 2019)  
583 with gene sets from the Broad Institute's MSigDB (Loures et al., 2015; Subramanian et al., 2005)  
584 collections; genes were ranked by the DESeq2 Wald statistic. Only pathways with an adjusted P  
585 value  $< 0.05$  were considered enriched. Expression heatmaps were generated using variance-

586 stabilized data, with the values centered and scaled by row. Code has been deposited to GitHub  
587 (<https://github.com/abcwcm/Guo2024>).

588

### 589 **RNAscope microscopy**

590 Formaldehyde-fixed, paraffin embedded (FFPE) surgical tissue Sects. FFPE tissue  
591 sections (5  $\mu$ m) were processed exactly as described in the manufacturer's instructions (ACD  
592 Bio, cat. no. 323100). Probes targeting the following genes were used: Ly6G (ACD Bio, cat. no.  
593 455701-C3), IFN $\lambda$ R (ACD Bio, cat. no. 512981-C1), IFN $\alpha$ R1 (ACD Bio, cat. no. 512971-C2).  
594 Slides were mounted with Prolong Diamond mounting media (ThermoFisher Scientific, cat. no.  
595 P36965). Slides were scanned using a Panoramic Digital Slide 517 Scanner (3DHISTECH,  
596 Budapest, Hungary) using a 20 $\times$ /0.8NA objective.

597

### 598 **Assay for transposase-accessible chromatin (ATAC) sequencing and epigenome analyses**

599 Freshly harvested WT and KO mouse neutrophils were directly sent to MSKCC's  
600 Epigenetics Research Innovation Lab. ATAC was performed as previously described (Corces et  
601 al. Nature Methods 2017) using 50,000 cells per replicate and the Tagment DNA TDE1 Enzyme  
602 (Illumina, 20034198). Sequencing libraries were prepared using the ThruPLEX DNA-Seq Kit  
603 (Takarabio, R400676) and sent to the MSKCC Integrated Genomics Operation core facility for  
604 sequencing on a NovaSeq 6000. Raw sequencing reads were trimmed and filtered for quality  
605 (Q>15) and adapter content using version 0.4.5 of TrimGalore  
606 ([https://www.bioinformatics.babraham.ac.uk/projects/trim\\_galore](https://www.bioinformatics.babraham.ac.uk/projects/trim_galore)) and running version 1.15 of  
607 cutadapt and version 0.11.5 of FastQC. Version 2.3.4.1 of bowtie2 (<http://bowtie->  
608 [bio.sourceforge.net/bowtie2/index.shtml](http://bio.sourceforge.net/bowtie2/index.shtml)) was employed to align reads to mouse assembly mm10

609 and alignments were deduplicated using Mark Duplicates in Picard Tools v2.16.0. Enriched  
610 regions were discovered using MACS2 (<https://github.com/taoliu/MACS>) with a p-value setting  
611 of 0.001, filtered for blacklisted regions  
612 ([http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/mm10-](http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/mm10-mouse/mm10.blacklist.bed.gz)  
613 [mouse/mm10.blacklist.bed.gz](http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/mm10-mouse/mm10.blacklist.bed.gz)), and a peak atlas was created using +/- 250 bp around peak  
614 summits. The BEDTools suite (<http://bedtools.readthedocs.io>) was used to create normalized  
615 bigwig files. Version 1.6.1 of featureCounts (<http://subread.sourceforge.net>) was used to build a  
616 raw counts matrix and DESeq2 was employed to calculate differential enrichment for all  
617 pairwise contrasts. Peak-gene associations were created by assigning all intragenic peaks to that  
618 gene, while intergenic peaks were assigned using linear genomic distance to transcription start  
619 sites (TSS).

620

## 621 **Histone and Transcription Factor CUT&RUN**

622 For CUT&RUN, 400,000 sorted neutrophils were used for H3K4me3 and STAT1  
623 analysis. Anti-H3K4me3 (Epicpyher, cat. no. 13-0028) or polyclonal anti-STAT1 antibodies  
624 (Proteintech, cat. no. 10144-2-AP) were employed for each target. Sorted cells were washed with  
625 PBS and resuspended in Antibody Buffer (1 × eBioscience Perm/Wash Buffer, 1× Roche  
626 cOmplete EDTA-free Protease Inhibitor, 0.5 μM Spermidine, and 2 μM EDTA in H<sub>2</sub>O). They  
627 were incubated overnight at 4°C with control IgG, H3K4me3, or STAT1 antibodies diluted  
628 1:100 in Antibody Buffer in a 96-well V-bottom plate. Following antibody incubation, cells were  
629 washed twice with Buffer 1 (1× eBioscience Perm/Wash Buffer, 1× Roche cOmplete EDTA-free  
630 Protease Inhibitor, 0.5 μM Spermidine in H<sub>2</sub>O) and resuspended in 50 μL of Buffer 1 plus 1×  
631 pA/G-MNase (Cell Signaling, cat. no. 57813). This mixture was incubated on ice for 1 hour, then

632 washed twice with Buffer 2 (0.05% w/v Saponin, 1× Roche cOmplete EDTA-free Protease  
633 Inhibitor, 0.5 μM Spermidine in 1X PBS) three times. Cells were resuspended in Calcium Buffer  
634 (Buffer 2 plus 2 μM CaCl<sub>2</sub>) and incubated on ice for 30 minutes to activate the pA/G-MNase  
635 reaction. An equal volume of 2× STOP Buffer (Buffer 2 plus 20 μM EDTA plus 4 μM EGTA)  
636 and 1 pg of *Saccharomyces cerevisiae* spike-in DNA (Cell Signaling, cat. no. 29987) were added.  
637 Samples were incubated at 37 °C for 15 minutes, followed by DNA isolation and purification  
638 using the Qiagen MinElute Kit per the manufacturer's instructions.

639 Immunoprecipitated DNA was quantified by PicoGreen, and the size was evaluated using  
640 an Agilent BioAnalyzer: fragments between 100 and 600 bp were size selected using aMPure XP  
641 beads (Beckman Coulter, cat. no. A63882). KAPA HTP Library Preparation Kit (Kapa  
642 Biosystems, cat. no. KK8234) was used to prepare Illumina sequencing libraries according to the  
643 manufacturer's instructions with 0.001–0.5 ng input DNA and 14 cycles of PCR. Barcoded  
644 libraries were run on the NovaSeq 6000 in a PE100 run using S4 kit version 1.5 with XP mode to  
645 generate approximately 23 million paired reads per sample.

646

#### 647 **CUT&RUN Data Processing**

648 CUT&RUN datasets were processed by trimming paired reads for adaptors and low-  
649 quality sequences using Trimmomatic (v0.39) and aligning to the mm10 reference genome with  
650 Bowtie 2 (v2.4.1). Peaks were identified using MACS2 (v2.2.7.1) with input samples as control,  
651 employing narrow peak parameters and cutoff - analysis - ple-5 - keep - dup all -B - SPMR.  
652 Irreproducible discovery rate (IDR) calculations were performed using ENCODE project scripts  
653 (IDR v2.0.4.2). Reproducible peaks with an IDR value of 0.05 or less in each condition were  
654 retained, aggregated, and merged to create the final atlas, which was annotated with the UCSC

655 Known Gene model. Reads were mapped to this atlas and counted using the summarize Overlaps  
656 function from the Genomic Alignment package (v1.34.1).

657

658 **Visualization.** Genomic tracks were visualized using GViz (v1.42.1) or IGV (v2.9.4).

659

## 660 **Quantitation and Statistical Analysis**

661 All data presented are representative of at least two independent experiments, as  
662 indicated. Unless stated otherwise, all results are expressed as mean ( $\pm$  SEM). We used the  
663 Mann-Whitney test for comparisons of two groups, and the Kruskal-Wallis test for multi-group  
664 comparisons, unless noted otherwise. Survival data were analyzed using the long-rank test. All  
665 statistical analyses were performed using GraphPad Prism software (v9.2.0).

666

## 667 **RESOURCE AVAILABILITY Lead Contact**

668 Further information and requests for resources or reagents should be directed to the Lead Contact,  
669 Tobias M. Hohl (hohlt@mskcc.org).

## 670 **Materials Availability**

671 This study did not generate new unique reagents.

## 672 **Data and Code Availability**

673 RNA sequencing data, ATAC sequencing data and CUT&RUN sequencing data were  
674 uploaded into NCBI database. Raw RNA sequencing datasets generated in this study are  
675 available at GSE280164. Raw ATAC sequencing data and CUT&RUN sequencing data  
676 generated in this study are available at GSE280229.



678 **Key Resources Table**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
APC Mouse anti-Mouse CD45.1 (clone A20)	BD Bioscience	Cat#558701; RRID: AB_1645214
PerCP-Cy <sup>TM</sup> 5.5 Mouse anti-Mouse CD45.2 (clone 104)	BD Bioscience	Cat#552950; RRID: AB_394528
APC-Cy <sup>TM</sup> 7 Rat anti-Mouse CD45 (clone 30- F11)	BD Bioscience	Cat#557659; RRID: AB_396774
PerCP-Cy <sup>TM</sup> 5.5 Rat anti-CD11b (clone M1/70)	BD Bioscience	Cat#550993; RRID: AB_394002
PE-Cy <sup>TM</sup> 7 Hamster anti-Mouse CD11c (clone HL3)	BD Bioscience	Cat#558079; RRID: AB_647251
BV 605 <sup>TM</sup> anti-mouse CD11c Antibody (clone N418)	BioLegend	Cat#117334; RRID: AB_117334
PE-Cy <sup>TM</sup> 7 Rat Anti-Mouse Ly-6C (clone AL- 21)	BD Bioscience	Cat#560593; RRID: AB_1727557
FITC Rat anti-Mouse Ly-6G (clone 1A8)	BD Bioscience	Cat#551460; RRID: AB_394207
FITC Rat anti-Mouse CD45R/B220 (clone RA3-6B2)	BD Bioscience	Cat#553087; RRID: AB_394617
PE anti-mouse CD183 Antibody (clone CXCR3-173)	BioLegend	Cat#126505; RRID: AB_1027656
BV421 Rat Anti-Mouse Siglec-F (clone E50- 2440)	BD Bioscience	Cat#562681; RRID: AB_2722581



BV605 Rat Anti-Mouse Siglec-H (clone 440c)	BD Bioscience	Cat#747673; RRID: AB_2744234
Purified Rat Anti-Mouse CD16/CD32 (clone 2.4G2)	BD Bioscience	Cat#553142; RRID: AB_394657
eFluor 450 NK1.1 Monoclonal Antibody (clone PK136)	eBioscience	Cat#48-5941-80; RRID: AB_2043878
eFluor 450 CD19 Monoclonal Antibody (clone eBio1D3)	eBioscience	Cat#48-0193-82; RRID: AB_2734905
Alexa Fluor 700, I-A/I-E Monoclonal Antibody (clone M5/114.15.2)	eBioscience	Cat#56-53-21; RRID: AB_494009
FITC Mouse IgG1 kappa Isotype Control	eBioscience	Cat#11-4714-42; RRID: AB_10596964
PE Rat IgG2a kappa Isotype Control	eBioscience	Cat#12-4321-42; RRID: AB_1518773
PerCP-Cyanine5.5 IgG Isotype Control	eBioscience	Cat#45-4888-80; RRID: AB_906260
APC Rat IgG2b kappa Isotype Control	eBioscience	Cat#17-4031-82; RRID: AB_470176
APC-eFluor 780 Rat IgG2b kappa Isotype Control	eBioscience	Cat#47-4031-80; RRID: AB_1272021
Alexa Fluor 700 Rat IgG2b kappa Isotype Control	eBioscience	Cat#56-4031-80; RRID: AB_837123
PE-Cyanine7 Rat IgG2a kappa Isotype Control	eBioscience	Cat#25-4321-82; RRID: AB_470200
eFluor 450 Rat IgG1 kappa Isotype Control	eBioscience	Cat#48-4301-82; RRID: AB_1271984

Bacterial and Virus Strains		
AF293	Fungal genetics stock center	#A1100
AF293 ds-Red	(Jhingran et al., 2016)	N/A
CEA10 (also known as CBS144.89)	(Girardin et al., 1993)	Received from Robert A. Cramer
Chemicals, Peptides, and Recombinant Proteins		
Alexa Fluor 633 succinimidyl ester	Invitrogen	Cat#S12375
Collagenase IV	ThermoFisher Scientific	Cat#LS004189
RPMI-1640	RPMI-1640	21870092
Enrofloxacin	Bayer	Baytril 100
Voriconazole	Pfizer	N/A
Tween-20	Sigma	P9416
Protease Inhibitor Cocktail	Roche	Cat#11697498001
DNase I, Grade II	Sigma	Cat#10104159001
isoflurane	Henry Schein Animal Health	Cat#29405
Diphtheria toxin (DT)	List Biological Laboratories	Cat#150
Paraformaldehyde, 32% Solution	ThermoFisher Scientific	Cat#50-980-495
CM-H <sub>2</sub> DCFDA	ThermoFisher Scientific	Cat#C6827
10× HBSS	ThermoFisher Scientific	14065056
TRIzol-LS	Invitrogen	10296028
Mouse IFN $\alpha$ 2/4 ELISA kit	Invitrogen	BMS6027
Mouse IL-28B/IFN-lambda 3 DuoSet ELISA	Invitrogen	DY1789B-05
Mouse GM-CSF DuoSet ELISA	Invitrogen	DY415-05
Mouse TNF alpha ELISA Ready-SET-Go! <sup>TM</sup> Kit	Invitrogen	50-173-31

Mouse IL-6 ELISA Ready-SET-Go! <sup>TM</sup> Kit	Invitrogen	50-172-19
Mouse IL-1 beta ELISA Kit	Invitrogen	BMS6002
Mouse IL-12 p70 ELISA Kit	Invitrogen	BMS6004
High-Capacity RNA-to-cDNA Kit	Appliedbiosystems	4387406
Ribosomal RNA Control Reagents	Appliedbiosystems	4308329
IFNa2 TaqMan Assay Mm00833961_s1	Thermo Fisher	4331182
IFNa1/a5/a6 TaqMan Assay Mm03030145_gH	Thermo Fisher	4331182
IFNL2/3 TaqMan Assay Mm04204155_gH	Thermo Fisher	4331182
Experimental Models: Organisms/Strains		
BDCA2-DTR	The Jackson Laboratory	JAX: 014176
C57BL/6	The Jackson Laboratory	JAX: 000664
C57BL/6.SJL	Taconic	Stock No. 4007
<i>Stat1</i> <sup>-/-</sup> mice	The Jackson Laboratory	JAX: 012606
<i>GBP</i> <sup>chr3-/-</sup> mice		Received from Dr. Thirumala-Devi Kanneganti.
<i>Cybb</i> <sup>-/-</sup> mice	The Jackson Laboratory	JAX: 002365
Software and Algorithms		
Prism 10	Prism 10	N/A
Flow Jo 10.10.0	Flow Jo 10.10.0	N/A

679

680

681

## 682 References

- 683 Abbas, A., T.P. Vu Manh, M. Valente, N. Collinet, N. Attaf, C. Dong, K. Naciri, R. Chelbi, G.  
684 Brelurut, I. Cervera-Marzal, B. Rauwel, J.L. Davignon, G. Bessou, M. Thomas-Chollier,  
685 D. Thieffry, A.C. Villani, P. Milpied, M. Dalod, and E. Tomasello. 2020. The activation  
686 trajectory of plasmacytoid dendritic cells in vivo during a viral infection. *Nat Immunol*  
687 21:983-997.
- 688 Antony, F., C. Pundkar, M. Sandey, A.K. Jaiswal, A. Mishra, A. Kumar, R. Channappanavar,  
689 and A. Suryawanshi. 2021. IFN-lambda Regulates Neutrophil Biology to Suppress  
690 Inflammation in Herpes Simplex Virus-1-Induced Corneal Immunopathology. *J Immunol*  
691 206:1866-1877.
- 692 Antos, D., O.B. Parks, A.M. Duray, N. Abraham, J.J. Michel, S. Kupul, R. Westcott, and J.F.  
693 Alcorn. 2024. Cell-intrinsic regulation of phagocyte function by interferon lambda during  
694 pulmonary viral, bacterial super-infection. *PLoS Pathog* 20:e1012498.
- 695 Ardanuy, J., K. Scanlon, C. Skerry, S.Y. Fuchs, and N.H. Carbonetti. 2020. Age-Dependent  
696 Effects of Type I and Type III IFNs in the Pathogenesis of Infection and Disease. *Journal*  
697 *of Immunology* 204:2192-2202.
- 698 Assil, S., S. Coleon, C. Dong, E. Decembre, L. Sherry, O. Allatif, B. Webster, and M. Dreux.  
699 2019. Plasmacytoid Dendritic Cells and Infected Cells Form an Interferogenic Synapse  
700 Required for Antiviral Responses. *Cell Host Microbe* 25:730-745 e736.
- 701 Ballesteros, I., A. Rubio-Ponce, M. Genua, E. Lusito, I. Kwok, G. Fernandez-Calvo, T.E.  
702 Khoyratty, E. van Grinsven, S. Gonzalez-Hernandez, J.A. Nicolas-Avila, T. Vicanelo, A.  
703 Maccataio, A. Benguria, J.L. Li, J.M. Adrover, A. Aroca-Crevillen, J.A. Quintana, S.  
704 Martin-Salamanca, F. Mayo, S. Ascher, G. Barbiera, O. Soehnlein, M. Gunzer, F.  
705 Ginhoux, F. Sanchez-Cabo, E. Nistal-Villan, C. Schulz, A. Dopazo, C. Reinhardt, I.A.  
706 Udalova, L.G. Ng, R. Ostuni, and A. Hidalgo. 2020. Co-option of Neutrophil Fates by  
707 Tissue Environments. *Cell* 183:1282-1297 e1218.
- 708 Berry, M.P., C.M. Graham, F.W. McNab, Z. Xu, S.A. Bloch, T. Oni, K.A. Wilkinson, R.  
709 Banchereau, J. Skinner, R.J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J.J. Cush,  
710 A. Mejias, O. Ramilo, O.M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, and A.  
711 O'Garra. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature  
712 in human tuberculosis. *Nature* 466:973-977.
- 713 Briard, B., R. Karki, R.K.S. Malireddi, A. Bhattacharya, D.E. Place, J. Mavuluri, J.L. Peters, P.  
714 Vogel, M. Yamamoto, and T.D. Kanneganti. 2019. Fungal ligands released by innate  
715 immune effectors promote inflammasome activation during *Aspergillus fumigatus*  
716 infection. *Nat Microbiol* 4:316-327.
- 717 Broggi, A., Y. Tan, F. Granucci, and I. Zanoni. 2017. IFN-lambda suppresses intestinal  
718 inflammation by non-translational regulation of neutrophil function. *Nat Immunol*  
719 18:1084-1093.
- 720 Brown, G.D., D.W. Denning, N.A. Gow, S.M. Levitz, M.G. Netea, and T.C. White. 2012.  
721 Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv113.
- 722 Chrysanthopoulou, A., K. Kambas, D. Stakos, I. Mitroulis, A. Mitsios, V. Vidali, I. Angelidou,  
723 M. Bochenek, S. Arelaki, A. Arampatzioglou, I.E. Galani, P. Skendros, E.A.Couladouros,  
724 S. Konstantinides, E. Andreakos, K. Schafer, and K. Ritis. 2017. Interferon lambda1/IL-  
725 29 and inorganic polyphosphate are novel regulators of neutrophil-driven  
726 thromboinflammation. *J Pathol* 243:111-122.

- 727 Desai, J.V., M.A. Zarakas, A.L. Wishart, M. Roschewski, M.A. Aufiero, Á. Donkó, G.  
728 Wigerblad, N. Shlezinger, M. Plate, M.R. James, J.K. Lim, G. Uzel, J.R. Bergerson, I.  
729 Fuss, R.A. Cramer, L.M. Franco, E.S. Clark, W.N. Khan, D. Yamanaka, G. Chamilos, J.  
730 El-Benna, M.J. Kaplan, L.M. Staudt, T.L. Leto, S.M. Holland, W.H. Wilson, T.M. Hohl,  
731 and M.S. Lionakis. 2024. BTK drives neutrophil activation for sterilizing antifungal  
732 immunity. *J Clin Invest* 134:0021-9738.
- 733 Dobin, A., C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, and  
734 T.R. Gingeras. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29:15-  
735 21.
- 736 Espinosa, V., O. Dutta, C. McElrath, P. Du, Y.J. Chang, B. Cicciarelli, A. Pitler, I. Whitehead,  
737 J.J. Obar, J.E. Durbin, S.V. Kotenko, and A. Rivera. 2017. Type III interferon is a critical  
738 regulator of innate antifungal immunity. *Sci Immunol* 2:2470-9468.
- 739 Espinosa, V., A. Jhingran, O. Dutta, S. Kasahara, R. Donnelly, P. Du, J. Rosenfeld, I. Leiner,  
740 C.C. Chen, Y. Ron, T.M. Hohl, and A. Rivera. 2014. Inflammatory monocytes  
741 orchestrate innate antifungal immunity in the lung. *PLoS Pathog* 10:e1003940.
- 742 Feys, S., A. Carvalho, C.J. Clancy, J.P. Gangneux, M. Hoenigl, K. Lagrou, B.J.A. Rijnders, L.  
743 Seldeslachts, L. Vanderbeke, F.L. van de Veerdonk, P.E. Verweij, and J. Wauters. 2024.  
744 Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill  
745 patients. *Lancet Respir Med* 12:728-742.
- 746 Fujimura, N., B. Xu, J. Dalman, H. Deng, K. Aoyama, and R.L. Dalman. 2015. CCR2 inhibition  
747 sequesters multiple subsets of leukocytes in the bone marrow. *Sci Rep* 5:11664.
- 748 Gerson, S.L., G.H. Talbot, S. Hurwitz, B.L. Strom, E.J. Lusk, and P.A. Cassileth. 1984.  
749 Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in  
750 patients with acute leukemia. *Ann Intern Med* 100:345-351.
- 751 Girardin, H., J.P. Latge, T. Srikantha, B. Morrow, and D.R. Soll. 1993. Development of DNA  
752 probes for fingerprinting *Aspergillus fumigatus*. *J Clin Microbiol* 31:1547-1554.
- 753 Guo, Y., S. Kasahara, A. Jhingran, N.L. Tosini, B. Zhai, M.A. Aufiero, K.A.M. Mills, M.  
754 Gjonbalaj, V. Espinosa, A. Rivera, A.D. Luster, and T.M. Hohl. 2020. During  
755 *Aspergillus* Infection, Monocyte-Derived DCs, Neutrophils, and Plasmacytoid DCs  
756 Enhance Innate Immune Defense through CXCR3-Dependent Crosstalk. *Cell host &*  
757 *microbe* 28:104-116 e104.
- 758 Hackstein, H., A. Wachtendorf, S. Kranz, J. Lohmeyer, G. Bein, and N. Baal. 2012.  
759 Heterogeneity of respiratory dendritic cell subsets and lymphocyte populations in inbred  
760 mouse strains. *Respir Res* 13:94.
- 761 Herbst, S., A. Shah, M. Mazon Moya, V. Marzola, B. Jensen, A. Reed, M.A. Birrell, S. Saijo, S.  
762 Mostowy, S. Shaunak, and D. Armstrong-James. 2015. Phagocytosis-dependent  
763 activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to  
764 *Aspergillus fumigatus*. *EMBO molecular medicine* 7:240-258.
- 765 Heung, L.J., A. Jhingran, and T.M. Hohl. 2015. Deploying FLAREs to Visualize Functional  
766 Outcomes of Host-Pathogen Encounters. *PLoS pathogens* 11:e1004912.
- 767 Hoenigl, M., D. Seidel, R. Sprute, C. Cunha, M. Oliverio, G.H. Goldman, A.S. Ibrahim, and A.  
768 Carvalho. 2022. COVID-19-associated fungal infections. *Nat Microbiol* 7:1127-1140.
- 769 Hohl, T.M., H.L. Van Epps, A. Rivera, L.A. Morgan, P.L. Chen, M. Feldmesser, and E.G. Pamer.  
770 2005. *Aspergillus fumigatus* triggers inflammatory responses by stage-specific beta-  
771 glucan display. *PLoS pathogens* 1:e30.

- 772 Jhingran, A., S. Kasahara, and T.M. Hohl. 2016. Flow Cytometry of Lung and Bronchoalveolar  
773 Lavage Fluid Cells from Mice Challenged with Fluorescent Aspergillus Reporter  
774 (FLARE) Conidia. *Bio Protoc* 6:2331-8325.
- 775 Korotkevich, G., V. Sukhov, and A. Sergushichev. 2019. Fast gene set enrichment analysis.  
776 *bioRxiv* 060012.
- 777 Kumar, A., D. Johnson, A. Bukowski, M.J. Noto, and N.H. Carbonetti. 2024. IFNlambda  
778 signaling in neutrophils enhances the pathogenesis of Bordetella pertussis infection. *J*  
779 *Leukoc Biol* 0741-5400.
- 780 Latgé, J.P., and G. Chamilos. 2019. Aspergillus fumigatus and Aspergillosis in 2019. *Clin*  
781 *Microbiol Rev* 33:0893-8512.
- 782 Lazear, H.M., T.J. Nice, and M.S. Diamond. 2015. Interferon-lambda: Immune Functions at  
783 Barrier Surfaces and Beyond. *Immunity* 43:15-28.
- 784 Liao, Y., G.K. Smyth, and W. Shi. 2014. featureCounts: an efficient general purpose program for  
785 assigning sequence reads to genomic features. *Bioinformatics* 30:923-930.
- 786 Lionakis, M.S., R.A. Drummond, and T.M. Hohl. 2023. Immune responses to human fungal  
787 pathogens and therapeutic prospects. *Nat Rev Immunol* 23:433-452.
- 788 Lionakis, M.S., K. Dunleavy, M. Roschewski, B.C. Widemann, J.A. Butman, R. Schmitz, Y.  
789 Yang, D.E. Cole, C. Melani, C.S. Higham, J.V. Desai, M. Ceribelli, L. Chen, C.J.  
790 Thomas, R.F. Little, J. Gea-Banacloche, S. Bhaumik, M. Stetler-Stevenson, S. Pittaluga,  
791 E.S. Jaffe, J. Heiss, N. Lucas, S.M. Steinberg, L.M. Staudt, and W.H. Wilson. 2017.  
792 Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. *Cancer*  
793 *Cell* 31:833-843 e835.
- 794 Lionakis, M.S., and S.M. Levitz. 2018. Host Control of Fungal Infections: Lessons from Basic  
795 Studies and Human Cohorts. *Annu Rev Immunol* 36:157-191.
- 796 Loures, F.V., M. Rohm, C.K. Lee, E. Santos, J.P. Wang, C.A. Specht, V.L. Calich, C.F. Urban,  
797 and S.M. Levitz. 2015. Recognition of Aspergillus fumigatus hyphae by human  
798 plasmacytoid dendritic cells is mediated by dectin-2 and results in formation of  
799 extracellular traps. *PLoS Pathog* 11:e1004643.
- 800 Love, M.I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion  
801 for RNA-seq data with DESeq2. *Genome Biol* 15:550.
- 802 Maldonado, S.D., J. Dai, O. Dutta, H.J. Hurley, S. Singh, L. Gittens-Williams, E. Kalyoussef,  
803 K.L. Edelblum, A. Rivera, and P. Fitzgerald-Bocarsly. 2022. Human Plasmacytoid  
804 Dendritic Cells Express C-Type Lectin Receptors and Attach and Respond to Aspergillus  
805 fumigatus. *J Immunol* 209:675-683.
- 806 Marciano, B.E., C. Spalding, A. Fitzgerald, D. Mann, T. Brown, S. Osgood, L. Yockey, D.N.  
807 Darnell, L. Barnhart, J. Daub, L. Boris, A.P. Rump, V.L. Anderson, C. Haney, D.B.  
808 Kuhns, S.D. Rosenzweig, C. Kelly, A. Zelazny, T. Mason, S.S. DeRavin, E. Kang, J.I.  
809 Gallin, H.L. Malech, K.N. Olivier, G. Uzel, A.F. Freeman, T. Heller, C.S. Zerbe, and  
810 S.M. Holland. 2015. Common severe infections in chronic granulomatous disease. *Clin*  
811 *Infect Dis* 60:1176-1183.
- 812 Mills, K.A.M., M.A. Aufiero, and T.M. Hohl. 2024. Epithelial responses to fungal pathogens.  
813 *Curr Opin Microbiol* 80:102508.
- 814 Montaldo, E., E. Lusito, V. Bianchessi, N. Caronni, S. Scala, L. Basso-Ricci, C. Cantaffa, A.  
815 Masserdotti, M. Barilaro, S. Barresi, M. Genua, F.M. Vittoria, G. Barbiera, D. Lazarevic,  
816 C. Messina, E. Xue, S. Markt, C. Tresoldi, R. Milani, P. Ronchi, S. Gattillo, L.  
817 Santoleri, R. Di Micco, A. Ditadi, G. Belfiori, F. Aleotti, M.M. Naldini, B. Gentner, E.

- 818 Gardiman, N. Tamassia, M.A. Cassatella, A. Hidalgo, I. Kwok, L.G. Ng, S. Crippa, M.  
819 Falconi, F. Pettinella, P. Scapini, L. Naldini, F. Ciceri, A. Aiuti, and R. Ostuni. 2022.  
820 Cellular and transcriptional dynamics of human neutrophils at steady state and upon  
821 stress. *Nat Immunol* 23:1470-1483.
- 822 Pollock, J.D., D.A. Williams, M.A. Gifford, L.L. Li, X. Du, J. Fisherman, S.H. Orkin, C.M.  
823 Doerschuk, and M.C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous  
824 disease, an inherited defect in phagocyte superoxide production. *Nat Genet* 9:202-209.
- 825 Preite, N.W., C. Feriotti, D. Souza de Lima, B.B. da Silva, A. Condino-Neto, A. Pontillo, V.L.G.  
826 Calich, and F.V. Loures. 2018. The Syk-Coupled C-Type Lectin Receptors Dectin-2 and  
827 Dectin-3 Are Involved in *Paracoccidioides brasiliensis* Recognition by Human  
828 Plasmacytoid Dendritic Cells. *Front Immunol* 9:464.
- 829 Ramirez-Ortiz, Z.G., C.A. Specht, J.P. Wang, C.K. Lee, D.C. Bartholomeu, R.T. Gazzinelli, and  
830 S.M. Levitz. 2008. Toll-like receptor 9-dependent immune activation by unmethylated  
831 CpG motifs in *Aspergillus fumigatus* DNA. *Infection and immunity* 76:2123-2129.
- 832 Rocha, B.C., P.E. Marques, F.M.S. Leoratti, C. Junqueira, D.B. Pereira, L. Antonelli, G.B.  
833 Menezes, D.T. Golenbock, and R.T. Gazzinelli. 2015. Type I Interferon Transcriptional  
834 Signature in Neutrophils and Low-Density Granulocytes Are Associated with Tissue  
835 Damage in Malaria. *Cell Rep* 13:2829-2841.
- 836 Seeds, R.E., S. Gordon, and J.L. Miller. 2009. Characterisation of myeloid receptor expression  
837 and interferon alpha/beta production in murine plasmacytoid dendritic cells by flow  
838 cytometry. *J Immunol Methods* 350:106-117.
- 839 Shlezinger, N., H. Irmer, S. Dhingra, S.R. Beattie, R.A. Cramer, G.H. Braus, A. Sharon, and T.M.  
840 Hohl. 2017. Sterilizing immunity in the lung relies on targeting fungal apoptosis-like  
841 programmed cell death. *Science* 357:1037-1041.
- 842 Sozzani, S., W. Vermi, A. Del Prete, and F. Facchetti. 2010. Trafficking properties of  
843 plasmacytoid dendritic cells in health and disease. *Trends Immunol* 31:270-277.
- 844 Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A.  
845 Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set  
846 enrichment analysis: a knowledge-based approach for interpreting genome-wide  
847 expression profiles. *Proc Natl Acad Sci U S A* 102:15545-15550.
- 848 Swiecki, M., S. Gilfillan, W. Vermi, Y. Wang, and M. Colonna. 2010. Plasmacytoid dendritic  
849 cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell  
850 accrual. *Immunity* 33:955-966.
- 851 Swiecki, M., H.L. Miller, R. Sesti-Costa, M. Cella, S. Gilfillan, and M. Colonna. 2017.  
852 Microbiota induces tonic CCL2 systemic levels that control pDC trafficking in steady  
853 state. *Mucosal Immunol* 10:936-945.
- 854 Taylor, P.R., G.D. Brown, D.M. Reid, J.A. Willment, L. Martinez-Pomares, S. Gordon, and S.Y.  
855 Wong. 2002. The beta-glucan receptor, dectin-1, is predominantly expressed on the  
856 surface of cells of the monocyte/macrophage and neutrophil lineages. *J Immunol*  
857 169:3876-3882.
- 858 Thompson, G.R., 3rd, and J.H. Young. 2021. *Aspergillus* Infections. *N Engl J Med* 385:1496-  
859 1509.
- 860 Tischler, B.Y., and T.M. Hohl. 2019. Menacing Mold: Recent Advances in *Aspergillus*  
861 Pathogenesis and Host Defense. *J Mol Biol* 431:4229-4246.

862 Varughese, T., Y. Taur, N. Cohen, M.L. Palomba, S.K. Seo, T.M. Hohl, and G. Redelman-Sidi.  
863 2018. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid  
864 Cancer. *Clin Infect Dis* 67:687-692.


865 Webster, B., S.W. Werneke, B. Zafirova, S. This, S. Coleon, E. Decembre, H. Paidassi, I.  
866 Bouvier, P.E. Joubert, D. Duffy, T. Walzer, M.L. Albert, and M. Dreux. 2018.  
867 Plasmacytoid dendritic cells control dengue and Chikungunya virus infections via IRF7-  
868 regulated interferon responses. *Elife* 7:2050-2084X

869 Xie, X., Q. Shi, P. Wu, X. Zhang, H. Kambara, J. Su, H. Yu, S.Y. Park, R. Guo, Q. Ren, S.  
870 Zhang, Y. Xu, L.E. Silberstein, T. Cheng, F. Ma, C. Li, and H.R. Luo. 2020. Single-cell  
871 transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. *Nat*  
872 *Immunol* 21:1119-1133.

873

874






875  
876 **Figure 1. pDC transcriptome following *A. fumigatus* infection.**

877 (A) Experimental scheme for bulk RNA-seq of BM pDCs sorted from naïve mice (red symbols)  
878 and BM (green symbols) and lung (blue symbols) pDCs sorted from *A. fumigatus*-infected mice.  
879 (B) Principal component analysis of gene expression in sorted BM pDCs from naïve (triangles)  
880 and infected mice (dots) and of sorted lung pDCs from naïve mice (squares). Each symbol  
881 represents a biological replicate. pDCs from 10 mice were pooled for each replicate, and 2  
882 replicates were included in each of 2 experiments, denoted as Expt1 (filled symbol) and Expt 2  
883 (open symbols). (C) Number of differentially expressed genes for three comparisons of 2 pDC  
884 subsets. (D) Differentially enriched KEGG pathways ( $q < 0.05$ ) in pDCs isolated from infected

885 lungs vs infected BM. Black bars indicate pathways enriched in lung pDCs from infected mice,  
886 white bars indicate pathways enriched in BM pDCs from infected mice. (E) Heatmap for 35  
887 selected genes with a >2 -fold difference in expression and a false discovery rate (FDR)  $p < 0.05$ .  
888 Each lane represents 1 replicate from 2 expts. (F - I) Representative flow cytometry plots (F and  
889 G) and quantified mean fluorescence intensity MFI (H and I) of IFN $\beta$ -YFP and ICAM-1  
890 expression in pDCs isolated from (top) naïve BM, (middle), the BM of *A. fumigatus*-infected  
891 mice or (bottom) the lungs of *A. fumigatus*-infected mice. (A-I) Infection dose:  $3 \times 10^7$  CEA10  
892 conidia via intratracheal route, analysis 72 hpi. (B - E) Data were pooled from 2 independent  
893 experiments. (H and I) Statistical analysis: Kruskal-Wallis test. See also Figure S1.

894



895

896 **Figure 2. Cytokine profiles in pDC-depleted mice during *A. fumigatus* infection**

897 (A - C) *Ifn* gene expression, measured by qRT-PCR using TaqMan probes, in the lung of

898 C57BL6/J mice at indicated times, n = 5-6 per group. (D) Lung *Ifn* gene expression and (E and


899 F) lung cytokine levels measured by ELISA in DT-treated pDC depletor mice (BDCA2-DTR<sup>Tg/+</sup>;

900 red symbols) and DT-treated non-Tg littermate controls (black dashed line), n = 8 per group. (A -

901 E) Infection dose:  $3 \times 10^7$  CEA10 conidia via intratracheal route, analysis 72 hpi. Data were

902 pooled from 2 independent experiments and presented as mean  $\pm$  SEM. Dots represent individual

903 mice. Statistical analysis: Kruskal-Wallis test



904

905 **Figure 3. STAT1 signaling regulates neutrophil-intrinsic *Aspergillus* killing.**


906 (A) Scheme to generate *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup> mixed bone marrow chimeric mice and (B) illustration of the

907 two-component fluorescent *Aspergillus* reporter (FLARE) system used to measure conidial

908 uptake and killing by *Stat1*<sup>-/-</sup> and *Stat1*<sup>+/+</sup> lung leukocytes in mixed bone marrow chimeric mice.

909 (C) Representative plot that display DsRed and AF633 fluorescence intensity of lung neutrophils.

910 The R1 gate denotes neutrophils that contain live conidia, the R2 gate denotes neutrophils that  
911 contain killed conidia. (D and E) The plots show (D) normalized lung neutrophil conidial uptake  
912  $(R1 + R2) \pm SEM$  and (E) conidial viability  $(R1 / (R1 + R2)) \pm SEM$  in indicated lung neutrophils  
913 isolated from *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black symbols) mixed BM chimeric mice  
914 (n=8 per group). (F) Scheme to generate *Stat1*<sup>-/-</sup> and WT (*Stat*<sup>+/+</sup>) chimeric mice. (G) Kaplan  
915 Meier survival of *Stat1*<sup>-/-</sup> and *Stat*<sup>+/+</sup> chimeric mice (n = 7-8 per group) infected with  $3-6 \times 10^7$   
916 CEA10 conidia. (H) Lung cytokine levels in *Stat1*<sup>-/-</sup> → WT (purple symbols) and *Stat1*<sup>+/+</sup> → WT  
917 (black symbols) single chimeric mice. (I) Representative plot and (J) mean  $\pm$  SEM neutrophil  
918 ROS production in cells isolated from *Stat1*<sup>-/-</sup> → WT (purple symbols) and *Stat1*<sup>+/+</sup> → WT (black  
919 symbols) single chimeric mice (n=5 per group). (C - E) Infection dose:  $3 \times 10^7$  Af293 FLARE  
920 conidia via intratracheal route, analysis 72 hpi. (F - I) Infection dose:  $3 \times 10^7$  CEA10 conidia via  
921 intratracheal route, analysis 72 hpi. (D and E) Data were pooled from 2 independent experiments.  
922 Dots represent individual mice. Statistical analysis: paired t test. (H - J) Data are representative  
923 of 2 experiments. Dots represent individual mice. Statistical analysis: Mann-Whitney test. See  
924 also Figure S2.



925

926 **Figure 4. pDCs regulate neutrophil STAT1-dependent antifungal activity.**

927 (A) Scheme to generate and to deplete pDCs or not in CD45.1<sup>+</sup> BDCA2- DTR<sup>Tg/+</sup> Stat1<sup>+/+</sup> and  
 928 CD45.2<sup>+</sup> BDCA2- DTR<sup>Tg/+</sup> Stat1<sup>-/-</sup> mixed bone marrow chimeric mice, resulting in 4


929 experimental groups (G1-G4). (B-D) (B) Representative plots that display DsRed and Af633

930 fluorescence intensity in lung neutrophils from 4 experimental groups: G1: pDC<sup>+</sup> Stat1<sup>+/+</sup>

931 (Stat1<sup>+/+</sup> neutrophils from pDC-sufficient mice), G2: pDC<sup>-</sup> Stat1<sup>+/+</sup> (Stat1<sup>+/+</sup> neutrophils from

932 pDC-depleted mice), G3: pDC<sup>+</sup> Stat1<sup>-/-</sup> (Stat1<sup>-/-</sup> neutrophils from pDC-sufficient mice), G4: pDC<sup>-</sup>

933 *Stat1*<sup>-/-</sup> (*Stat1*<sup>-/-</sup> neutrophils from pDC-depleted mice). The R1 gate indicates the frequency of  
934 neutrophils that contain live conidia, the gate R2 indicates the frequency of neutrophils that  
935 contain killed conidia. (C and D) The plots show mean neutrophil (C) conidial uptake (R1 + R2)  
936 ± SEM and (D) conidial viability (R1/ (R1 + R2) ± SEM in indicated lung neutrophils isolated  
937 from the 4 groups, n = 12 per group, data pooled from 2 experiments. (E) Mean ± SEM ROS  
938 production in indicated lung neutrophils, n = 6 per group. (B - D) Infection dose:  $3 \times 10^7$  Af293  
939 FLARE conidia via intratracheal route, analysis 72 hpi. (C and D) Data were pooled from 2  
940 independent experiments and presented as mean ± SEM, (E) Data are representative of 2  
941 experiments. Dots represent individual mice. Statistical analysis: Kruskal-Wallis test. See also  
942 Figure S3.  
943




944  
 945 **Figure 5. STAT1-dependent guanylate-binding proteins are dispensable for the neutrophil**  
 946 **antifungal response.**

947 (A) Principal component analysis of global gene expression, (B) differentially enriched KEGG  
 948 pathways, and (C) Volcano plot of differentially expressed genes in *Stat1*<sup>-/-</sup> (purple symbols) and  
 949 *Stat1*<sup>+/+</sup> (black symbols) neutrophil sorted from mixed bone marrow chimeric mice (n = 6) at 72  
 950 hpi with 3 × 10<sup>7</sup> CEA10 conidia. Selected downregulated genes in *Stat1*<sup>-/-</sup> neutrophils are  
 951 highlight in the Volcano plot. (D) Experimental scheme to generate *GBP*<sup>chr3-/-</sup> and *GBP*<sup>chr3+/-</sup>  
 952 single chimeric mice. (E) Kaplan Meier survival (n = 7-8 per group), and (F) mean ± SEM lung  
 953 CFU (n = 5 per group) in *GBP*<sup>chr3-/-</sup> (red symbols) and *GBP*<sup>chr3+/-</sup> (black symbols) single  
 954 chimeric mice infected with 3-6 × 10<sup>7</sup> CEA10 conidia. (G) Experimental scheme to generate




955 *GBP<sup>chr3-/-</sup>* and *GBP<sup>chr3+/+</sup>* mixed chimeric mice. (H and I) The plots show normalized neutrophil  
956 (H) conidial uptake (R1 + R2) ± SEM and (I) conidial viability (R1/ (R1 + R2) ± SEM in lung  
957 neutrophils isolated from *GBP<sup>chr3-/-</sup>* (red symbols) and *GBP<sup>chr3+/+</sup>* (black symbols) mixed bone  
958 marrow chimeric mice (n = 6 per group). (J) Mean ± SEM neutrophil ROS production in  
959 neutrophils isolated from *GBP<sup>chr3-/-</sup>* (red symbols) and *GBP<sup>chr3+/+</sup>* (black symbols) mixed bone  
960 marrow chimeric mice (n=6 per group). (H - J) Infection dose:  $3 \times 10^7$  Af293 FLARE conidia  
961 via intratracheal route, analysis 72 hpi. (F, H - J) Data are representative of 2 experiments and  
962 presented as mean ± SEM. Dots represent individual mice. Statistical analysis: Mann-Whitney  
963 test.  
964



965  
966 **Figure 6. STAT1-dependent control of *Cybb* expression and CYBB protein levels in**  
967 **neutrophils.**

968 (A) Heatmap of *Cybb*, *Cyba*, *Ncf1*, *Ncf3*, *Ncf4*, *Nox1*, *Nox3*, and *Nox4* expression in neutrophils  
969 sorted from *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black symbols) mixed bone marrow chimeric  
970 mice (n = 6). Genes with a STAR\* are DEG. Each lane is an independent biological replicate. (B)  
971 qRT-PCR of *Cybb* mRNA expression in neutrophils sorted from *Stat1*<sup>-/-</sup> (purple symbols) and

972 *Stat1*<sup>+/+</sup> (black symbols) mice. (C) ATAC-seq analysis of neutrophils were sorted from *Stat1*<sup>-/-</sup>  
973 (purple peaks) and *Stat1*<sup>+/+</sup> (black peaks) mice. Gene tracks show chromatin accessibility at the  
974 *Cybb* and *Gbp2* locus. (D) Bone marrow and lung neutrophils were sorted from *Stat1*<sup>-/-</sup> (purple  
975 peaks) and *Stat1*<sup>+/+</sup> (black peaks) mice and processed for CUT&RUN. Gene tracks show STAT1  
976 signal as normalized fragment pileup (y-axis) plotted by genome position (x-axis). The shaded  
977 box highlights a putative STAT1 binding site at the *Gbp2* promoter region. Gene tracks show  
978 H3K4me3 ChIP-seq signal as normalized fragment pileup (top rows; green). (E - H) Western  
979 blot and quantitation of (F) CYBB, (G) CYBA, (H) NCF4 vs GAPDH protein levels in lung  
980 neutrophils sorted from *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black symbols) mice, neutrophils  
981 from 4-5 mice were pooled to obtain sufficient protein for Western blot analysis in each  
982 biological replicate. (A - H) Infection dose:  $3 \times 10^7$  CEA10 conidia via intratracheal route,  
983 analysis 72 h pi. (C) Data were calculated by Kruskal-Wallis nonparametric test for multiple  
984 comparisons for each group compared with control group. (G - I) Data are representative of 2  
985 experiments. Dots represent individual mice. Statistical analysis: Mann-Whitney test. See also  
986 Figure S4.  
987




988

989 **Figure S1. Related to Fig. 1. pDC transcriptome analysis following *A. fumigatus* infection.**

990 (A) The plots indicate the FACS sorting strategy for BM and lung pDCs (top row) and the

991 typical (>95%) pDC purity after FACS sorting (bottom row). (B) Volcano plot of the


992 differentially expressed genes in pDCs sorted from the bone marrow of infected vs. naïve mice.  
993 (C) Volcano plot of the differentially expressed genes in pDCs sorted from infected lungs vs  
994 naïve bone marrow. (D) Volcano plot of the differentially expressed genes in pDCs sorted from  
995 infected lungs vs infected bone marrow. (E) The plot shows differentially enriched KEGG  
996 pathways ( $q < 0.05$ ) observed in pDCs isolated from infected lungs vs infected BM. Black  
997 bars indicate pathways enriched in lung pDCs from infected mice, white bars indicate pathways  
998 enriched in BM pDCs from infected mice.



999

1000 **Figure S2. Related to Fig. 3. Type I and III IFN receptor expression on Ly6G<sup>+</sup> lung**  
1001 **neutrophils.**

1002 (A) Lung sections from naïve and *A. fumigatus*-infected mice were analyzed by RNAscope using  
1003 probes to Ly6G (first column) and IFNαR1 (second column), and DAPI (third column), and  
1004 merged images are shown in fourth column, and yellow arrows indicate examples of co-  
1005 localization of the Ly6G and IFNαR1 probes within the same nuclei. (B) Lung sections from  
1006 naïve and *A. fumigatus*-infected mice were analyzed by RNAscope using probes to Ly6G (first  
1007 column) and IFNλR1 (second column), and DAPI (third column), and merged images are shown  
1008 in fourth column, and yellow arrows indicate examples of co-localization of the Ly6G and  
1009 IFNλR1 probes within the same nuclei. (A and B) Infection dose:  $3 \times 10^7$  CEA10 conidia via  
1010 intratracheal route, analysis at 72 hpi. Scale bar = 20 μm.




1011

1012

1013 **Figure S3. Related to Fig. 4. STAT1 modulates the neutrophil antifungal response.**

1014 (A) Lung cytokine levels measured by ELISA of *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black  
1015 symbols) mice. (B - E) Lung (B) neutrophil, (C) monocyte, (D) Mo-DC and (E) pDC numbers in  
1016 *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black symbols). (A - E) Infection dose:  $3 \times 10^7$  CEA10  
1017 conidia via intratracheal route, analysis 72 hpi. Data are representative of 2 experiments. Dots  
1018 represent individual mice. Statistical analysis: Mann-Whitney test.

1019



1020  
1021

1022 **Figure S4. Related to Fig. 6. *Cybb*<sup>-/-</sup> mice are susceptible to *A. fumigatus* infection.**

1023 (A) *Cybb* gene expression in neutrophils isolated from *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup>

1024 (black symbols) mice. Gene expression as determined by qRT-PCR (n = 3 - 5 per group) (B)

1025 Kaplan Meier survival (n = 7 - 8 per group) of *Cybb*<sup>-/-</sup> (blue symbols) and WT control (black

1026 symbols) mice infected with 3 - 6 × 10<sup>7</sup> CEA10 conidia. (C) Genome browser tracks of ATAC-

1027 seq data at the *Cybb* locus in lung neutrophils isolated from *Stat1*<sup>-/-</sup> (purple symbols) and

1028 *Stat1*<sup>+/+</sup> (black symbols) mice. (D) Statistics of peaks at indicated *Cybb* loci in lung neutrophils


1029 isolated from *Stat1*<sup>-/-</sup> (purple symbols) and *Stat1*<sup>+/+</sup> (black dash line) mice. (A - D) Infection dose:

1030 3 × 10<sup>7</sup> CEA10 conidia via intratracheal route, analysis 72 hpi. \*P < 0.05; \*\*P < 0.01; \*\*\*P <

1031 0.001. Data presented as mean ± SEM. Dots represent individual mice. Statistical analysis:

1032 Kruskal-Wallis test for multiple comparisons.





1033

1034 **Graphic abstract**

- 1035 • pDC activation in the infected lung coincides with type I and type III interferon
- 1036 production.
- 1037 • pDCs represent a major, but not exclusive source of type I and type III IFN in the
- 1038 *Aspergillus*-infected lung.
- 1039 • These pDC-derived products act on type I and type III IFN receptor<sup>+</sup> lung neutrophils via
- 1040 STAT1 signal transduction.
- 1041 • STAT1-dependent neutrophil fungal killing and ROS production is attenuated in the
- 1042 absence of pDCs.
- 1043 • STAT1 expression regulates *Cybb* transcription and CYBB protein levels in neutrophils,
- 1044 but does not regulate the transcription or translation of other subunits of neutrophil
- 1045 NADPH oxidase.